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Mutations in DNA methyltransferase 3A (DNMT3A) have been detected in autism and related disorders, but
how these mutations disrupt nervous system function is unknown. Here, we define the effects of DNMT3A
mutations associated with neurodevelopmental disease. We show that diverse mutations affect different as-
pects of protein activity but lead to shared deficiencies in neuronal DNAmethylation. Heterozygous DNMT3A
knockout mice mimicking DNMT3A disruption in disease display growth and behavioral alterations consis-
tent with human phenotypes. Strikingly, in these mice, we detect global disruption of neuron-enriched
non-CG DNAmethylation, a binding site for the Rett syndrome protein MeCP2. Loss of this methylation leads
to enhancer and gene dysregulation that overlaps with models of Rett syndrome and autism. These findings
define the effects of DNMT3A haploinsufficiency in the brain and uncover disruption of the non-CG methyl-
ation pathway as a convergence point across neurodevelopmental disorders.
INTRODUCTION
Precise regulation of transcription is critical for nervous system
development, and exome sequencing studies have revealedmu-
tations in genes encoding epigenetic modifiers of chromatin
structure as major underlying causes of neurodevelopmental
disease (NDD) (McRae et al., 2017; Sanders et al., 2015). A chal-
lenge emerging from these discoveries is to define the cellular
functions of the disrupted proteins during normal development
and to search for shared pathways between these proteins
that may be targeted for therapy development.
Gene regulation by DNA methylation has emerged as an
epigenetic mechanism critical for nervous system function
(Kinde et al., 2015). In addition to classical methylation of cyto-
sines found at CG dinucleotides (mCG), neurons contain
uniquely high levels of methyl-cytosine (mC) in a non-CG
context, with this mark occurring primarily at CA sites (mCA)
(Lister et al., 2013; Xie et al., 2012). mCA is deposited by DNA
methyltransferase 3A (DNMT3A) during the early postnatal
period (1–6 weeks of age in mice) until the number of non-CG
methylation sites in neurons is nearly equivalent to the number
of mCG sites (Lister et al., 2013; Xie et al., 2012). mCA serves
as a critical binding site for methyl-CpG binding protein 2
(MeCP2) (Chen et al., 2015; Gabel et al., 2015; Guo et al.,
2014). MeCP2 was initially defined by its high affinity for mCG;
however, it also tightly interacts with mCA to downregulate tran-
scription of genes with essential functions in the brain (Kinde
et al., 2016; Lagger et al., 2017; Lyst and Bird, 2015). Loss of
MeCP2 leads to the severe neurological disorder Rett syndrome,
whereas duplication causes MeCP2 duplication syndrome, an
autism spectrum disorder (ASD) (Amir et al., 1999; Van Esch
et al., 2005), indicating that mCA readout is critical for nervous
system function.
Exome sequencing studies have identified heterozygous mu-
tations in DNMT3A in ASD (Feliciano et al., 2019; Iossifov et al.,
2014; Sanders et al., 2015; Satterstrom et al., 2019). Separate
studies have also defined heterozygous disruption of DNMT3A
as the cause of Tatton-Brown Rahman syndrome (TBRS), an
NDD characterized by intellectual disability (ID), overgrowth,
craniofacial abnormalities, anxiety, and ASD (Tatton-Brown
et al., 2014, 2018). Although some mutations in affected individ-
uals are truncations predicted to cause complete enzyme loss, a
majority of NDD-associated alleles are missense mutations,
raising questions about whether loss-of-function effects are a
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primary mechanism in DNMT3A disorders (Tatton-Brown et al.,
2014, 2018). In addition, the large percentage of missense muta-
tions in affected individuals raises the need to establish the
deleterious effects of these mutations to definitively associate
mutations with NDD and end the ‘‘diagnostic odyssey’’ for pa-
tients (Sawyer et al., 2016). Finally, although heterozygous loss
of DNMT3A has been studied in the context of hematopoietic
oncogenesis (Cole et al., 2017), the effects of partial loss of
DNMT3A on neuronal DNA methylation, gene expression, and
brain function have not been investigated closely.
Here we examine the molecular effects of NDD-associated
DNMT3A mutations and explore how heterozygous loss of
DNMT3A affects the neuronal epigenome. We show that
missense mutations across domains of DNMT3A disrupt
different aspects of protein function, but all mutations reduce
deposition of neuronal mCA. Using DNMT3A heterozygous dele-
tion mice, we assess the effect of shared loss-of-function effects
resulting from missense and deletion mutations. We detect
altered growth and behavior in these mice, suggesting that hap-
loinsufficiency contributes to pathology in DNMT3A disorders.
Through integrated epigenomics analysis, we reveal a global
reduction of mCA throughout the brains of DNMT3A mutants.
We show that loss of mCA leads to disruption of distal regulatory
enhancer activity and changes in gene expression that overlap
with models of MeCP2 disorders and other NDDs. These find-
ings define the effects of NDD-associated DNMT3A mutations
and implicate disruption of mCA-mediated epigenomic regula-
tion as a convergence site across clinically distinct NDDs.
RESULTS
Functional Analysis of NDD-Associated DNMT3A
Mutations
Multiple DNMT3A mutations have been identified in individuals
with ASD and TBRS. However, the myriad missense mutations
identified and the phenotypic heterogeneity of affected individ-
uals suggests that altered amino acids in different protein do-
mains may have distinct consequences that dictate the nature
and severity of disease. Furthermore, it is not clear whether
missense mutations identified in patient populations are truly
disruptive, raising the need for direct assessment of molecular
function to ascribe mutations as potentially causative. We there-
fore assessed the effects of NDD-associated DNMT3A muta-
tions on protein expression, cellular localization, and catalytic
activity, looking for common effects that may be core to NDD.
We introducedalterations homologous to humandiseasemuta-
tions into a FLAG-tagged DNMT3A expression vector (Figure 1A;
Table S1), assessing mutations within the chromatin interacting
proline-tryptophan-tryptophan-proline (PWWP) domain, the
auto-inhibitory ATRX-DNMT3-DNMT3L (ADD) domain, and the
methyltransferase domain (Gowher and Jeltsch, 2018). Transfec-
tion into heterologous cells facilitated assessment of protein
expression by western blot, cellular localization by immunocyto-
chemistry, and catalytic activity using an in vitromethyltransferase
assay. Mutations in the PWWP domain resulted in reduced
DNMT3A protein and loss of nuclear localization (Figures 1B–
1D; Figures S1A–S1C). When expressed at equal levels as wild-
type protein, however, these mutants exhibited normal in vitro
methyltransferase activity (Figures 1E and 1F). In contrast, muta-
tions found in the catalytic domain of DNMT3A showed wild-
type expression and localization but had deficits in methyltrans-
ferase activity (Figures 1B–1Fl Figures S1A–S1C). Mutations in
the ADDdomain of DNMT3Adisplayed normal protein localization
and expression levels and exhibited equal or higher methylation
activity compared with the wild type (Figures 1B–1F; Figures
S1A–S1C).
To further evaluate the effects of DNMT3A mutations in the
context of endogenous chromatin, we tested the capacity of
DNMT3A mutants to establish DNA methylation in mouse
cortical neurons. For this analysis, we focused on the
DNMT3A-dependent build-up of mCA in postmitotic neurons
(Gabel et al., 2015; Lister et al., 2013). Cultured embryonic day
14.5 cortical neurons accumulate mCA in vitro, and this build-
up is blocked by lentivirus-mediated delivery of Cre recombinase
to DNMT3Aflx/flx cells at 3 days in vitro (DIV) (Figure 2A; Figures
S1D and S1E). We co-transduced Cre with wild-type or mutant
DNMT3A lentiviruses at equal levels (Figure S1F) to test each
protein for rescue of mCA deposition. All NDD-associated muta-
tions across domains of DNMT3A blocked mCA accumulation
when tested in neurons (Figure 2B). Notably, ADD domain muta-
tions that exhibited robust catalytic activity in vitro displayed
moderate to severe deficits in mCA deposition. The ADD domain
has been implicated in histone binding and autoinhibition of the
protein (Guo et al., 2015); thus, the results of this neuronal assay
suggest that loss of ADD function blocks DNMT3A from
engaging chromatin and promoting methylation in cells. Disease
mutations associated with ID (Table S1) show near-complete
loss of mCA rescue, whereas mutations associated with ASD
but not ID (such as V665L) have more moderate depletion of
mCA. This suggests that a possible gradient of disease pheno-
types may be driven by differential mutation severity. Unlike
mCA, global mCG levels show no significant differences in this
in vitro system, likely because of the redundant function of the
DNMT1 methyltransferase in maintaining mCG sites (Figures
S1G and S1H). Together our results indicate that, although
NDD-associated mutations in DNMT3A affect different protein
domains and alter distinct functions (e.g., localization, chromatin
interaction, and catalysis), these mutations share a common
outcome of reduced enzymatic activity on neuronal DNA, with
multiple mutations resulting in functionally null proteins.
In Vivo Growth and Behavioral Effects of Heterozygous
DNMT3A Disruption
Our in vitro finding that multiple NDD-associated DNMT3A
missense mutations result in severe loss of function, coupled
with identification of deletion and nonsense mutations in TBRS
patients, suggests that an 50% reduction of DNMT3A activity
occurs in a substantial fraction of affected individuals. Thus,
studying the effects of heterozygous inactivation of DNMT3A
in vivo can provide an understanding of the epigenomic and sys-
tems-level consequences of DNMT3A disruption in NDD. Previ-
ous studies have demonstrated severe developmental deficits,
disruptions in movement, and lethality upon constitutive com-
plete loss of DNMT3A (homozygous null mutation; Okano
et al., 1999) or removal of DNMT3A from the brain (conditional
DNMT3A deletion; Nguyen et al., 2007). However, the growth




and behavioral effects of heterozygous DNMT3A inactivation
have not been assessed systematically. We therefore carried
out growth, behavioral, and molecular analyses of mice carrying
a constitutive heterozygous deletion of exon 19 ofDnmt3a (STAR
Methods; Kaneda et al., 2004).We find that thismutation leads to
50% reduction of RNA and protein expression, allowing us to
study the in vivo effects of the heterozygous null mutation of
DNMT3A (referred to as DNMT3AKO/+) (Figures S2A–S2C).
We first examined phenotypes relevant to overgrowth in indi-
viduals with TBRS (Tatton-Brown et al., 2018), including
enlarged body size and obesity (body weight), tall stature
(long-bone length), and macrocephaly (skull dimensions).
DNMT3AKO/+ mice showed similar body weights as controls in
the early postnatal period but were significantly heavier as adults
(Figure 3A). This phenotype mimics a maturity-associated trend
toward increased body weight in TBRS patients (Tatton-Brown
et al., 2018). Measurements of leg bone length, a major determi-
nant of human height (Duyar and Pelin, 2003), showed increases
in the DNMT3AKO/+ mice, with significantly increased tibia length
and a trend toward longer femur length (Figure 3B; Figures S3A–
S3D). Morphometric analyses of the cranium and mandible indi-
cated very subtle differences between DNMT3AKO/+ and wild-
type littermates (Figures S3E–S3G). The rostrocaudal length of
the interparietal bone was larger in DNMT3AKO/+ mice, whereas
two facial linear distances were significantly larger in the wild
type (Figure S3E). These findings uncover effects on bone length
and body weight that mirror aspects of the human disorder,
whereas skull development in DNMT3AKO/+ mice shows more
limited effects.
To examine neurological and behavioral phenotypes in
DNMT3AKO/+ mice, we first assessed basic measures of sensa-
tion and motor performance, such as balance (ledge test and
platform test), grip strength (inverted screen test), motor coordi-
nation (walking initiation and rotarod), and sensorimotor gating
Figure 1. NDD-Associated DNMT3A Mutations Disrupt Distinct Aspects of Protein Function
(A) Schematic of the human DNMT3A protein, showing the canonical domains and NDD-associated mutations (Sanders et al., 2015; Tatton-Brown et al., 2018)
tested in this study.
(B) Example immunoblot of DNMT3A mutant protein expression in Neuro-2a cells.
(C) Example images of DNMT3A protein immunocytochemistry from the wild type and PWWP domain mutant in Neuro-2a cells. Scale bar, 20 mm.
(D) Quantification of DNMT3A mutant protein localization (n = 6–16 images; generalized linear model test with Bonferroni correction).
(E) Schematic of the in vitro methylation assay for DNMT3A mutant proteins isolated from HEK293T cells.
(F) Activity of DNMT3A mutant proteins in the in vitro methylation assay, normalized to wild-type (WT) DNMT3A (set equal to 1) and GFP-only (set equal to 0)
controls (n = 4–19; one-sample t test with Bonferroni correction).
*p < 0.05, **p < 0.01, ***p < 0.001, #p < 0.0001. Bar graphs indicate mean and SEM. See also Figure S1 and Table S1.




(pre-pulse inhibition). DNMT3AKO/+ mice were not significantly
different in these assays (Figures S4A–S4G), indicating that het-
erozygous loss of DNMT3A does not grossly disrupt sensori-
motor function. This allowed us to assessmore complex aspects
of behavior and cognition.
We next carried out assays with relevance to neuropathology
in humans with DNMT3A mutations, including anxiety, autism,
and ID. In open field testing, DNMT3AKO/+ mice explored the
chamber less than wild-type mice, as indicated by reduced dis-
tance traveled and rearing (Figures 3C and 3D). DNMT3AKO/+
mice also displayed anxiety-like behavior, measured by less
time in the center of the arena in this assay (Figure 3E). In tests
of climbing behavior, DNMT3AKO/+ mice showed longer latency
to climb to the bottom of a pole and to the top of mesh screens
(Figures S4H–S4J), suggesting that DNMT3AKO/+ mice display
differences in volitional movement. During assessment of anxi-
ety-like behavior in the elevated plus maze, DNMT3AKO/+ mice
spent less time exploring the open arms of the maze, with no
change in the percentage of entriesmade into all arms (Figure 3F;
Figure S4K). Overall, these results indicate that DNMT3AKO/+
mice display changes in exploratory behavior, suggesting
altered emotionality and increased anxiety-like behaviors.
ID is a highly penetrant phenotype in TBRS. We therefore
assessed learning and memory in DNMT3AKO/+ mice using
contextual fear conditioning and Morris water maze tests. In
foot shock-induced fear conditioning, DNMT3AKO/+ mutants
showed a heightened freezing response during training and in
the contextual and auditory recall phases (Figures 3G–3I; Figures
S4L and S4M). Mutant mice also showed delayed extinction of
freezing behavior in response to the auditory cue alone (Fig-
ure S4M). These effects do not arise from differential responses
to shock pain (Figure S4N), further suggesting altered emotion-
ality or cognition in the mutant mice. During assessment of
spatial and contextual memory in the Morris water maze,
DNMT3AKO/+ mice were slower to learn to find a visible platform
and did not learn the location of the hidden platform over time as
well as wild-type controls (Figures S4O and S4P), despite similar
swimming speeds (Figures S4Q and S4R). There were no signif-
icant effects on distance traveled in target zone or platform
crossings in the probe trial, although DNMT3AKO/+ mice trended
toward fewer platform crossings (Figures S4S and S4T). These
findings suggest that DNMT3AKO/+ mutants do not show severe
deficits in learning and memory but display differences in task
performance that may reflect altered emotionality or cognition.
DNMT3A has been identified as a high-confidence autism
gene (Sanders et al., 2015), and autism is commonly diagnosed
in TBRS patients (Tatton-Brown et al., 2018). We therefore char-
acterized phenotypes examined in models of autism (marble
burying, three-chamber social approach, and ultrasonic vocali-
zations). We detected a significant reduction in marble-burying
activity for DNMT3AKO/+ mice, indicating alterations in repetitive
digging behavior (Figure 3J; Figure S4U). Evaluation of social
interaction behaviors in the three-chamber social approach
assay (Yang et al., 2011) revealed that DNMT3AKO/+ mice spend
reduced time investigating mice and objects, with no change in
preference index for sociability or novelty (Figures S5A–S5D; Ny-
gaard et al., 2019). We considered that testing under normal
lighting and experimental conditions may induce anxiety in addi-
tion to probing sociability and that the reduced exploration of
DNMT3AKO/+ mice may reflect the anxiety-like phenotypes
rather than sociability changes. Indeed, when repeating the
three-chamber analysis under low lighting conditions to mitigate
anxiety in themice, we detected similar exploratory behavior, so-
ciability, and social novelty responses in wild-type and
DNMT3AKO/+ mice (Figures S5E–S5H; Manno et al., 2020). To
explore changes in pro-communication behaviors, wemeasured
maternal isolation-induced ultrasonic vocalizations (Barnes
et al., 2017). We detected a reduction in the number of calls in
DNMT3AKO/+ mice on post-natal day 5, suggesting deficits in
early pro-social behaviors or developmental delay in acquisition
of this behavior (Figure 3K). These results reveal alterations in be-
haviors commonly assessed in mouse models of autism (Chang
et al., 2017; Kazdoba et al., 2014; Takumi et al., 2020), with our
findings suggesting reduced activity and exploration as well as
changes in communication behaviors.
Overall, our physiological and behavioral analyses demon-
strate that heterozygous deletion of DNMT3A results in growth
and behavior changes in mice with relevance to the overgrowth,
Figure 2. NDD-Associated DNMT3A Muta-
tions Prevent Buildup of Neuronal CA
Methylation
(A) Schematic of DNMT3A functional analysis in
primary culture neurons. Cortical neurons are
harvested from DNMT3Aflx/flx mice at embryonic
day 14.5 (E14.5) and cultured. After 3 days in vitro
(DIV), neurons are virally transduced with Cre re-
combinase and WT or mutant FLAG-tagged
DNMT3A. On DIV 12.5, DNA and RNA are
collected. Equal DNMT3A mRNA expression is
verified by qRT-PCR (Figure S1F), and DNA is used
for whole-genome bisulfite sequencing analysis.
(B) Relative mCA amount compared with Cre only
(set equal to 0) and Cre+WT DNMT3A (set equal to
1) controls (n = 4–11; one-sample t test with Bon-
ferroni correction).
*p < 0.05, **p < 0.01, ***p < 0.001, #p < 0.0001. Bar
graphs indicatemean and SEM. See also Figure S1
and Table S1.




anxiety, communication, and memory-associated phenotypes
observed in patients with DNMT3A mutations. These data sup-
port a model in which DNMT3A haploinsufficiency contributes
to altered growth and behavioral circuits to drive phenotypes in
NDD.
Global Disruption of DNAMethylation in the DNMT3AKO/
+ Brain
We next investigated the epigenomic defects that may underlie
the altered behaviors in DNMT3AKO/+ mice. We first used sparse
whole-genome bisulfite sequencing to survey the effects on
global methylation levels in multiple brain regions and the liver.
This analysis detected limited reductions in genome-wide
mCG levels in the DNMT3AKO/+ brain that were not apparent in
non-neuronal tissue (liver) (Figure 4A). In contrast, mCA levels
were reduced 30%–50% across all DNMT3AKO/+ brain regions
examined (Figure 4B). Analysis of DNA methylation during post-
natal development in the cerebral cortex, a region with high adult
mCA levels, suggested that these deficits appear during accu-
mulation of mCA (Figure 4B). Thus, global mCA levels in the brain
Figure 3. Heterozygous Disruption of DNMT3A In Vivo Leads to Growth and Behavioral Alterations
(A) Body weight of DNMT3AKO/+ and WT mice at three time points (male p = 0.038 genotype by age interaction, F(2,50) = 3.494, n = 6–18; female p = 0.0032
genotype by age interaction, F(2,48) = 6.498; female p = 0.0016 genotype effect, F(1,48) = 11.18, n = 5–17; two-way ANOVA).
(B) Bone lengths shown as standard deviations from the WT mean for DNMT3AKO/+ mice (n = 12; paired t test).
(C) Total ambulations during 1-h open-field testing (10-min bins, p = 0.0008 genotype effect, F(1,46) = 13.02, n = 21, 27; two-way repeated-measures (RM) ANOVA
with Sidak’s multiple comparison test).
(D) Rearing events during 1-h open-field testing (10-min bins, p = 0.0103 effect by genotype, F(1,46) = 7.161, n = 21, 27; two-way RM ANOVA with Sidak’s multiple
comparison test).
(E) Time in the center zone during open field testing (p = 0.0075, n = 21, 27; unpaired t test).
(F) Percentage of time in the open arms during elevated plus maze testing (p = 0.0069; n = 33, 39; unpaired t test).
(G–I) Percentage of time freezing in (G) conditioned fear training (baseline: p = 0.0071 genotype effect, F(1,50) = 7.897; cue: p = 0.0013 genotype effect, F(1,50) =
11.7; n = 26; two-way RM ANOVA with Sidak’s multiple comparisons test), (H) contextual fear trials (p = 0.0215, n = 26; unpaired t test), and (I) cued fear trials
(before cue: p = 0.0606; after cue: p = 0.00014; n = 26; unpaired t test).
(J) Marbles buried in 30 min (5-min bins, p = 0.0374 effect by genotype, F(1,25) = 4.834, n = 14, 13; two-way RM ANOVA with Sidak’s multiple comparison test).
(K) Number of ultrasonic calls from isolated pups for 3mine of testing at the indicated ages; p = 0.0378 genotype effect, F(1,285) = 4.355, n = 9–46; two-way ANOVA
with Sidak’s multiple comparisons test.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Boxplots show 10th–90th percentiles of data. Line and bar graphs indicate mean and SEM. See also Figures
S2–S5.




are sensitive to heterozygous DNMT3A disruption, whereas
global mCG levels are largely maintained.
DNA methylation at genomic elements such as promoters, en-
hancers, and gene bodies can regulate transcription, and altered
methylation at these regions can affect gene expression to affect
brain function (Clemens et al., 2019; Nord andWest, 2020; Stroud
et al., 2017). We therefore performed base-pair-resolution, high-
depth, whole-genome bisulfite sequencing to identify potential
changes in mCG and mCA at these important regulatory sites.
We focused on the cerebral cortex because this region is enriched
for mCA (Figure 4B) and disrupted in ASD and MeCP2 disorders
(Clemens et al., 2019; Satterstrom et al., 2019). Our analysis of
mCG confirmed the subtle mCG reduction across classes of
genomic elements (Figures 5A–5D). We considered, however,
that CG dinucleotides at specific sites may be more sensitive to
partial DNMT3A reduction. For example, in the hematopoietic sys-
tem, heterozygous DNMT3A loss leads to mCG reductions in
genomic regions identified as sensitive to complete loss of
DNMT3A (Cole et al., 2017). We therefore evaluated CG differen-
tially methylated regions (CG-DMRs) identified previously as
becoming highly methylated in the adult cortex (Figure S6A; Lister
et al., 2013), hypothesizing that these adult-specific CG-DMRs
might be sensitive to a reduction in enzyme activity. Indeed, we
found that these sites build up mCG during postnatal develop-
ment and do not becomemethylated in a brain-specific DNMT3A
conditional knockout mouse (DNMT3ANestin-cKO) (Stroud et al.,
2017; Figure S6B). Analysis of these adult-specific CG-DMRs in
DNMT3AKO/+ mice indicated that they are particularly sensitive
to partial inactivation of DNMT3A (Figures 5A, 5C, and 5D).
Because a substantial portion ofmCG in neurons is oxidized to
hydroxymethylation (hmCG), we performed oxidative bisulfite
sequencing of DNMT3AKO/+ cortex DNA. This analysis revealed
no evidence of widespread differential effects on oxidized or un-
oxidized forms of mCG across genomic regions (Figure S6C),
suggesting that hmCG is largely preserved in the DNMT3AKO/+
brain. However, future experiments will be required to uncover
whether there are site-specific changes in hmCG.
To further search for local sites of alteredmCG in DNMT3AKO/+,
we performed de novo calling of CG-DMRs using the BSmooth al-
gorithm (Hansen et al., 2012). We identified 6,164 hypo- and 378
hyper-CG-DMRs that met stringent size and reproducibility filters
(Figures 5A–5C, and 5E; Figure S6D; Table S2; STAR Methods).
Hypo-CG-DMRs significantly overlap with adult-specific CG-
DMRs (Lister et al., 2013; Figure 5F; Figure S6E), further support-
ing the idea that DNMT3A is haploinsufficient for postnatal mCG
deposition at these sites. Significant overlap of DNMT3AKO/+
hypo-CG-DMRswas also detected for putative enhancer regions,
gene bodies, and promoters (Figures 5A–5C and 5F; Figure S6E).
DMRs were also highly enriched for overlap with CpG island
shores, regions disrupted in studies of DNMT3A mutation outside
of the nervous system (Cole et al., 2017; Spencer et al., 2017; Fig-
ure 5C; Figure S6E). These findings indicate that specific mCG
sites are sensitive to heterozygous DNMT3A loss and that locali-
zation of these CG-DMRs to regulatory elements could affect
gene expression.
We next examinedmCA in the DNMT3AKO/+ cortex at genomic
elements with relevance to gene regulation. In contrast to
changes in mCG levels, mCA levels were reduced 30%–50%
at gene bodies, promoters, and CpG island shores (Figure 5G).
CpG islands displayed less reduction of mCA, possibly because
of floor effects in bisulfite sequencing (STAR Methods).
ComparingmCA changeswithin genomic elements as a function
of wild-typemCA levels revealed consistent reductions indepen-
dent of the normal levels of mCA (Figure S6F). This result sug-
gests that mCA loss in the DNMT3AKO/+ cortex does not prefer-
entially affect specific classes of genomic elements, nor is it
more severe in some regions, based on the level of mCA nor-
mally deposited there.
Recent analysis has shown that topologically associating do-
mains (TADs) of chromatin folding affect gene regulation by influ-
encing DNMT3A binding and subsequent mCA deposition
(Clemens et al., 2019; Nothjunge et al., 2017). The average
mCA level in TADs is associated with mCA levels at enhancers
found in those TADs, and high-mCA enhancers within high-
mCA TADs are robust targets of MeCP2 repression (Clemens
et al., 2019). We therefore assessed mCA levels at TADs and en-
hancers genome wide. This analysis detected reductions in TAD
mCA levels similar tomCA reductions at other genomic elements
(Figure 5G). Enhancers also showed pervasive depletion of mCA
(Figure 5G). Thus, widespread mCA loss for TADs and the
enhancer elements within them occurs in DNMT3AKO/+ mice
and can affect control of regulatory elements by MeCP2.
Figure 4. Global DNA Methylation Levels upon Heterozygous Loss
of DNMT3A
(A and B) Global mCG (A) andmCA levels (B) in DNA isolated frombrain regions
of 8-week-old mice (left) (unpaired t test with Bonferroni correction) and
developmental time course of global mCG in the cerebral cortex (right), as
measured by sparse whole-genome bisulfite sequencing (WGBS) (p < 0.0001
effect by genotype, F(1,27) = 1024; p < 0.0001 effect by age F(5,27) = 884.6; n = 3-
4; two-way ANOVA). Bonferroni corrected p values are indicated on the x axis.
*p < 0.05, ***p < 0.001. Line graphs indicate mean and SEM. See also Fig-
ure S6.




Enhancer Dysregulation Results from Methylation
Deficits in DNMT3AKO/+ Mice
We next examined how disruption of DNA methylation affects
epigenetic regulation and gene expression in the DNMT3AKO/+
brain. Recent analyses indicate that MeCP2 binds mCA to
mediate neuron-specific gene regulation, in part by controlling
the activity of enhancer elements (Boxer et al., 2020; Clemens
et al., 2019). Loss of MeCP2 leads to genome-wide upregulation
Figure 5. High-Resolution Analysis of DNA Methylation Changes in the DNMT3AKO/+ Cerebral Cortex
(A) Genomebrowser views ofmCA andmCG inWT andDNMT3AKO/+ cerebral cortices, measured byWGBS. A broad view shows global reduction inmCA (left). A
gray dashed line facilitates comparison of mCA levels across genotypes. Shown is magnification of DNMT3AKO/+ hypo-CG-DMRs overlapping an enhancer
(center) or a CpG-island shore and an adult-specific DMR (right). AWTH3K27acChIP-seq signal (Clemens et al., 2019), peaks of enhancer-associated histone H3
lysine 4 methylation (H3K4me1) and promoter-associated histone H3 lysine 4 tri-methylation (H3K4me3) (Stamatoyannopoulos et al., 2012), CpG islands, and
gene annotations (Haeussler et al., 2019) are also shown.
(B and C) Overlay of the mCG signal for DMRs shown in (A).
(D) Violin plot of mCG/CG levels (top) and percent reduction (bottom) in DNMT3AKO/+ versus WT across genomic regions. Dots indicate mean mCG/CG per
bioreplicate (n = 4 per genotype; paired t test, Bonferroni correction).
(E) Heatmap of CG-DMRs called in the DNMT3AKO/+ cortex across bioreplicates (B1–B4).
(F) Overlap of CG-DMRs with genomic regions (Fisher’s exact test, observed versus background estimated from resampled DMRs; STAR Methods).
(G) Violin and percent reduction plots as in (D) but for mCA/CA.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Bar graphs indicate mean and SEM. See also Figure S6.




of the histone H3 lysine 27 acetylation (H3K27ac) active mark at
enhancers that contain many mCA and mCG sites, whereas
overexpression of MeCP2 leads to reciprocal downregulation
of these enhancers. This altered enhancer activity in MeCP2mu-
tants is linked to gene dysregulation that likely contributes to ner-
vous system dysfunction (Clemens et al., 2019). These studies
suggest that reduced mCA in DNMT3AKO/+ would remove bind-
ing sites forMeCP2 in enhancers and result in enhancer dysregu-
lation that partially phenocopies effects observed in MeCP2
mutant mice. To investigate this possibility directly, we quanti-
fied the change in mCA binding sites in DNMT3AKO/+ for en-
hancers found previously to be significantly repressed by
MeCP2 (Clemens et al., 2019). We found that, because these
MeCP2-repressed enhancers contain large numbers of mCA
sites, the global 30%–50% reduction of mCA in DNMT3AKO/+
leads to a larger loss in mCA sites at these enhancers than at
other enhancers genome wide (Figures 6A and 6B). Thus,
MeCP2-repressed enhancers are particularly susceptible to
mCA binding site loss from heterozygous DNMT3A mutation.
To determine whether mCA reductions at MeCP2-repressed
enhancers affects their activity, we performed H3K27ac chro-
matin immunoprecipitation sequencing (ChIP-seq) analysis of
the DNMT3AKO/+ and wild-type cortex. This analysis revealed
significant acetylation changes at MeCP2-repressed enhancers
(Figures 6A and 6C). Consistent with these effects arising from
partial loss of mCA that normally builds up post-mitotically at en-
hancers, we detect changes that are concordant with but smaller
than effects observed upon complete mCA ablation in a neuron-
specific DNMT3A cKOmouse (DNMT3A Baf53b-cKO) (Clemens
et al., 2019; Figure 6C). We also find that enhancers within high-
mCA TADs show significantly higher increases in acetylation
compared with enhancers in other TADs (Figure S6G), further
supporting a model in which high mCA levels in TADs lead to
repression of enhancers in these TADs by mCA and MeCP2.
Although significantly dysregulated enhancers are detected in
MeCP2 mutants, broad sub-significance-threshold effects also
occur genome wide upon MeCP2 mutation, with enhancers
across the genome undergoing dysregulation that is proportional
to the number of mC binding sites they contain (Figure 6D; Clem-
ens et al., 2019). Analysis of H3K27ac changes at enhancers
genome wide based on the normal density of mCA sites they
contain revealed broad mCA-associated derepression of en-
hancers in the DNMT3AKO/+ cortex that is similar to but smaller
in magnitude than effects in DNMT3A Baf53b-cKO and MeCP2
knockout (KO) mice. These effects are also reciprocal to effects
observed in MeCP2 overexpression (OE) mice. Consistent with
limited global mCG disruption in DNMT3AKO/+, there was only
a limited association between changes in enhancer activity and
the normal level of mCG. This finding contrasts with MeCP2 mu-
tants, where loss of protein binding to mCG andmCA sites leads
to enhancer dysregulation associated with mCA and mCG
(Clemens et al., 2019; Figure 6D).
Although there is limited evidence that a global change inmCG
affects enhancers in DNMT3AKO/+, we considered that site-spe-
cific changes in mCG (DMRs) may have functional effects at
these regions. Indeed, we found that enhancers overlapping
hypo-CG-DMRs in DNMT3AKO/+ showed subtle but significant
increases in acetylation compared with enhancers without a
DMR (Figure S6H). These results suggest that site-specific
enhancer mCG changes in DNMT3AKO/+ have functional effects.
Our epigenomic analyses demonstrate that loss of many of the
normal mCA sites in the DNMT3AKO/+ cortex results in enhancer
dysregulation that overlaps with MeCP2mutant mice. On amore
limited scale, loss of CG methylation at specific enhancers can
also affect enhancer activity. These findings uncover a role of
shared neuronal chromatin pathology between DNMT3A and
MeCP2 disorders.
Overlapping Transcriptional Pathology between
DNMT3AKO/+, MeCP2 Disorders, and ASD
The epigenetic changes we observe in DNMT3AKO/+ cerebral
cortex can have direct consequences on gene expression to
drive neurological dysfunction inmice. Furthermore, overlapping
enhancer effects in DNMT3AKO/+ and MeCP2 mutants suggest
that shared transcriptional pathology may occur upon loss of
mCA in DNMT3A disorders and in MeCP2 disorders. We there-
fore assessed changes in gene expression in DNMT3AKO/+
mice, interrogating whether these effects overlap with those
observed upon ablation of mCA in DNMT3A Baf53b-cKO and
loss or OE of MeCP2 in MeCP2 mutants. RNA sequencing
(RNA-seq) of the DNMT3AKO/+ cerebral cortex identified subtle
mRNA and non-coding RNA changes that are consistent in
magnitude with small effects observed in other heterozygous
NDD models (Fazel Darbandi et al., 2018; Gompers et al.,
2017; Katayama et al., 2016; Figures S7A and S7B; Tables S3
and S4).
Gene Ontology analysis of gene expression changes detected
terms associated with neurodevelopment processes, such as
axon guidance and recognition, that occur before and during
the period when DNMT3A deposits mCA in the brain (Fig-
ure S7C). This is consistent with a role of DNMT3A in regulating
transcriptional programs as neurons mature. Additionally, we
see significantly reduced expression of relevant ASD genes,
Shank2 and Shank3, which suggests dysfunction at the synaptic
level (Table S3) (Guilmatre et al., 2014). These results suggest
that genes critical for development of neural circuits are affected
in DNMT3AKO/+ mice.
To determine whether transcriptional dysregulation upon
disruption of DNMT3A and MeCP2 results in shared effects,
we examined the overlap of significantly dysregulated genes
across mutant mouse lines. We found that the genes dysregu-
lated in the DNMT3AKO/+ overlap extensively with the gene
sets dysregulated in DNMT3A Baf53b-cKO and MeCP2 mutants
(Figure 6E). For example, all three models show upregulation of
Shroom3, whose mutation is associated with developmental de-
fects in humans (Deshwar et al., 2020), and latrophilin-2, a post-
synaptic adhesion molecule with roles in synapse targeting and
assembly in multiple brain regions (Anderson et al., 2017; Zhang
et al., 2020). Shared dysregulation of genes like these in
DNMT3A and MeCP2 disorders may contribute to synaptic
dysfunction and disease pathology.
Although a limited gene set is detected as significantly dysre-
gulated in DNMT3AKO/+, we considered whether genome-wide
enhancer changes could lead to widespread, subtle dysregula-
tion of gene expression below the significance threshold
for detection. Such transcriptional pathology would mirror




subthreshold genome-wide effects observed upon loss of
neuronal mCA (DNMT3A Baf53b-cKO) and in models of Rett
syndrome (MeCP2 KO) and ASD (MeCP2 OE) (Clemens et al.,
2019; Gabel et al., 2015). Importantly, evidence from MeCP2
mutants suggests that pathology arises from thousands of small
changes in gene expression rather than large changes in a few
significant genes (Lavery and Zoghbi, 2019; Kinde et al., 2016).
Disruption of the neuronal methylome in DNMT3AKO/+ could
similarly lead to numerous gene expression changes that escape
statistical significance but still contribute to pathology. To
assess whether sub-significance level changes in DNMT3AKO/+
phenocopy the MeCP2 mutant and DNMT3A Baf53b-cKO
models, we performed generally applicable gene set enrichment
(GAGE) analysis (Luo et al., 2009). GAGE analysis revealed highly
Figure 6. Epigenetic and Transcriptomic Dysregulation in the DNMT3AKO/+ Cerebral Cortex Overlaps with MeCP2 Mutants
(A) Genome browser view of DNAmethylation and H3K27ac ChIP-seq data fromWT and DNMT3AKO/+ (top). Shown are an overlaid H3K27ac signal andmCA/CA
at enhancers defined previously as dysregulated upon disruption of mCA or MeCP2 (Clemens et al., 2019) (bottom).
(B)MeanmCA sites per kilobase inWT andDNMT3AKO/+ (top) andmCA sites per kilobase lost in DNMT3AKO/+ (bottom) for enhancers significantly dysregulated in
MeCP2 mutants (**p < 0.01, ***p < 0.001; n = 4; paired t test with Bonferroni correction).
(C) Boxplot of change in H3K27ac signal in DNMT3ABaf53b-cKO and DNMT3AKO/+ for enhancers defined as significantly dysregulated inMeCP2mutants (***p <
108, ****p < 1012; n = 5 bioreplicates; Wilcoxon test).
(D) Heatmap of H3K27ac changes for mutants across deciles of enhancers sorted by WT mCA or mCG sites per kilobase.
(E) Overlap of significantly dysregulated genes (padj. < 0.1) in DNMT3AKO/+ and genes dysregulated in DNMT3A Baf53b-cKO or MeCP2 mutants (***p < e5,
****p < e10; hypergeometric test, observed versus background estimated by resampling; STAR Methods).
(F) Significance of gene set expression changes in DNMT3AKO/+ for GAGE analysis of gene sets dysregulated in DNMT3A Baf53b-cKO or MeCP2 mutants
(Clemens et al., 2019). Boxplots indicate median and quartiles. Bar graphs indicate mean and SEM.
See also Figures S6 and S7.




significant, concordant changes in gene expression in
DNMT3AKO/+ for gene sets dysregulated in DNMT3A Baf53b-
cKO and MeCP2 mutants (Figure 6F).
To further explore the model in which loss of methylation and
enhancer dysregulation drives DNMT3AKO/+ gene expression
changes, we examined enhancers associated with significantly
upregulated genes. We found that these enhancers show pro-
nounced loss of mCA sites and display significant increases in
enhancer acetylation compared with other enhancers in
DNMT3AKO/+ (Figures S7D and S7E). Analysis of genes contain-
ing enhancers harboring a hypo-CG-DMR also detected signifi-
cant upregulation of expression compared with other genes (Fig-
ure S7F), suggesting that local changes in mCG contribute to
DNMT3AKO/+ transcriptomic changes.
We next explored whether shared gene expression signatures
in DNMT3AKO/+ mice extend to models of NDD without estab-
lished mechanistic links to DNMT3A. GAGE analysis detected
significant alterations in genes identified as dysregulated in
CHD8 and PTEN mouse models of overgrowth and ASD (Gom-
pers et al., 2017; Katayama et al., 2016; Tilot et al., 2016) as
well as the SETD5 NDD model (Sessa et al., 2019; Figure 7A).
These findings suggest that overlapping gene dysregulation
could underlie common symptomology in individuals with muta-
tions in distinct epigenomic regulatory genes. Extending GAGE
analysis to human ASD data, we observed significant changes
of gene sets dysregulated in ASD postmortem brains (Gandal
et al., 2018; Voineagu et al., 2011) in the DNMT3AKO/+ cortex
(Figure 7B) and also detected upregulation of genes linked to
ASD from human genetics studies (Abrahams et al., 2013; Bane-
rjee-Basu and Packer, 2010; Figure 7B). In addition, we detected
overlap of DNMT3AKO/+ gene dysregulation with neurodevelop-
mental gene co-expression modules identified in the human
brain (Parikshak et al., 2013), including M13, M16, and M17,
which increases during cortical development and are enriched
for ASD risk genes (Figure S7G). Modules involved in gene regu-
lation that are expressed early in development and decrease
over time (M2 and M3) are also increased in DNMT3AKO/+ (Fig-
ure S7G). Resampling analysis indicated that significant dysre-
gulation of these mouse and human gene sets in DNMT3AKO/+
is not driven by enriched expression in the cortex (Figure S7H).
These findings suggest that the DNMT3AKO/+ mouse shares
overlapping transcriptional pathology with gene expression
changes underlying NDD.
DISCUSSION
Our findings here provide an initial working model of molecular
etiology in DNMT3A disorders. Diverse de novomissense muta-
tions in affected individuals disrupt the enzyme by disabling
chromatin localization in the nucleus, disrupting the ADD-regula-
tory domain, or impairing methyltransferase activity. Insufficient
DNMT3A activity because of these missense mutations, or early
truncations and deletions in other individuals, causes deficits in
deposition of mCG at specific sites during development and a
massive deficit in postnatal mCA accumulation throughout the
brain. These changes in DNA methylation lead to alterations in
epigenomic regulation, including subtle but widespread disrup-
tion of mCA-MeCP2-mediated enhancer regulation in adult neu-
rons, resulting in gene expression changes that contribute to
deficits in nervous system function.
Our study provides insights into the molecular effects of
DNMT3A mutations and serves as a model to understand the
functional effects of diverse de novo mutations underlying
NDD. When exome sequencing studies identify heterozygous
missense mutations in patients with NDD (McRae et al., 2017;
Satterstrom et al., 2019), it can be unclear whether simple hap-
loinsufficiency contributes to pathology or whether more com-
plex functional effects occur because of individual amino acid al-
terations. In addition, although identification of many mutations
in a gene can indicate that disruption of the gene causes NDD,
a subset of observedmissensemutationsmay not be deleterious
enough to be the pathological driver in the individual in whom
they are found. Thus, functional testing of these variants is
necessary to determine whether they may underlie disease. In
our study, the deleterious effects we observed for each mutation
suggest that they are causative, but it was only by assessing
multiple aspects of DNMT3A function (i.e., expression, localiza-
tion, activity, and cellular mCA levels) that we detected deficits
for each variant. For example, ADD domain mutations only
disrupt deposition of mCA in cells, possibly because of loss of
regulation that is only necessary in the endogenous chromatin
context. Our findings establish loss of function effects of diverse
DNMT3A mutations and underscore the importance of multidi-
mensional analysis of de novo mutations to fully assess their
role in NDD.
Our in vivo analyses revealed increased long-bone length,
increased body weight, anxiety-like phenotypes, deficits in
Figure 7. GeneDysregulation in DNMT3AKO/
+ Overlaps with Effects in Other NDDs
(A) GAGE analysis of expression changes in
DNMT3AKO/+ for dysregulated gene sets in studies
of NDD mouse models (Gompers et al., 2017;
Katayama et al., 2016; Sessa et al., 2019; Tilot
et al., 2016).
(B) GAGE analysis of expression changes in
DNMT3AKO/+ for gene sets identified in studies of
human ASD. ASD modules 12 (synaptic) and 16
(immune) were identified previously in weighted
gene coexpression analysis of human ASD brains
(Voineagu et al., 2011), and ASD-dysregulated
genes were also identified previously (Abrahams
et al., 2013; Gandal et al., 2018). See also Fig-
ure S7.




pro-social communication, and alterations in repetitive behav-
iors in DNMT3AKO/+ mice that mirror key features of DNMT3A
disorders. In contrast, lack of severe deficits in learning and
memory assays in the DNMT3AKO/+ mouse may indicate that
cognitive processes aremore susceptible to DNMT3A disruption
in humans than in mice. However, we do detect subtly altered
behavior in these assays, and the lack of strong deficits may
reflect insensitivity of the methods to measure cognition in
mice. Our in vivo analyses uncover effects of heterozygous
DNMT3A deletion that can be probed at the molecular, cellular,
and organismal levels in future studies.
We employed the DNMT3AKO/+ experimental system to
assess how heterozygous DNMT3A loss affects epigenetic regu-
lation in the brain. We detected subtle changes in mCG genome
wide across brain regions, with no global mCG effects in non-
neural tissue. These limited mCG effects are likely due to redun-
dant function of the maintenance methyltransferase DNMT1,
which can preserve existing mCG patterns during cell divisions
(Jeltsch et al., 2018). In addition, the de novo methyltransferase
DNMT3B is expressed with DNMT3A in many tissues during
early development and may provide redundancy for mCG
patterning (Okano et al., 1999). The focal loss of mCG we do
observe in the brain (i.e., hypo-CG-DMRs) often overlaps with
regulatory elements that aremethylated postnatally by DNMT3A.
This mCG loss has the potential to disrupt gene expression and
neurological function in DNMT3AKO/+ mice. In addition, site-spe-
cific changes inmCGare likely to occur in early development and
in non-neural tissues. For example, constitutive heterozygous
deletion of DNMT3A disrupts mCG patterns in the blood and al-
ters hematopoietic lineages (Cole et al., 2017). Such changes in
mCG can contribute to growth and other phenotypes observed
in mice and humans.
In contrast to mCG, we detect a global 30%–50% reduction in
mCA in multiple brain regions of DNMT3AKO/+. These results
extend findings from the hypothalamus (Sendzikait _e et al.,
2019), demonstrating broad sensitivity to heterozygous
DNMT3A loss. The susceptibility of mCA to reduced DNMT3A
is likely due to DNMT3B not being expressed in postnatal neu-
rons (Lister et al., 2013), and DNMT1 cannot deposit mCA
(Jeltsch et al., 2018), making all neuronal mCA build-up depen-
dent on DNMT3A. In addition, DNMT3A has slow kinetics for
CA methylation (Zhang et al., 2018), and deposition of mCA
genome-wide must take place in a restricted time window (1–
6 weeks) when the enzyme is highly expressed in neurons (Lister
et al., 2013). These constraints may make enzyme levels limiting
for mCA accumulation in neurons and explain the sensitivity to
DNMT3A gene dosage. Notably, our findings suggest that acti-
vating the remaining DNMT3A or prolonging its high postnatal
expression might rescue mCA deposition deficits. Conversely,
duplication of the DNMT3A gene could result in too much mCA
deposition and cause neural dysfunction akin toMeCP2 duplica-
tion disorder. Future studies can assess the feasibility of rescue
approaches and explore whether DNMT3A duplication alters
brain function.
Our analysis of chromatin changes downstream of altered
DNA methylation has uncovered a striking point of shared mo-
lecular disruption across models of DNMT3A disorders, Rett
syndrome, and MeCP2 duplication syndrome. Although the clin-
ical profile of DNMT3A disorders is distinct from MeCP2 disor-
ders, we show here that loss of approximately a quarter of
MeCP2 binding sites in the DNMT3AKO/+ cortex results in subtle
but widespread disruption of mCA-associated enhancer regula-
tion that partially phenocopies loss of MeCP2. This enhancer
dysregulation is further linked to shared gene expression
changes in these models. Given the critical roles of MeCP2-
regulated genes in nervous system function (Gabel et al., 2015;
Lagger et al., 2017), these overlapping epigenomic and tran-
scriptomic effects likely contribute to neurological dysfunction
in DNMT3A disorders.
Overall, the deficits observed in theDNMT3AKO/+mice are less
severe than in DNMT3A cKO and MeCP2 knockout mice, which
present with decreases in motor coordination, severely reduced
body size, and increased mortality (Nguyen et al., 2007; Tillotson
et al., 2017). These differences mirror differential effects on mCA
deposition and readout in these strains; DNMT3A cKO loses all
neuronal mCA and MeCP2 KO loses a major reader of mCA
andmCG, whereas DNMT3AKO/+ loses only half of themCA sites
and a localized set of mCG sites. The persistence of many mCA
and mCG binding sites for MeCP2 in DNMT3AKO/+ may partially
explain how DNMT3A mutations in humans manifest with less
severe symptomology than in Rett syndrome. Absence of
DNMT3A early in prenatal development and loss of DNMT3A
functions that are independent of MeCP2 (Lavery et al., 2020)
are likely to drive overgrowth and other non-overlapping aspects
of DNMT3A and MeCP2 disorders. Our findings show that
disruption of enhancer regulation by mCA-MeCP2 likely
contributes to multiple distinct disorders, defining a site of
convergent molecular etiology underlying heterogeneous clinical
syndromes.
Our transcriptomics analysis of changes in ASD/NDD gene
sets in DNMT3A mice has detected overlap beyond MeCP2 dis-
orders, including mouse NDD/ASD models (e.g., CHD8) and
gene sets identified in human ASD. As additional NDD transcrip-
tomics studies of mouse and human brain emerge, systematic
analyses can identify shared aspects of transcriptional pathol-
ogy across diverse causes of NDD. Notably, the large number
of chromatin-modifying enzymes mutated in NDD suggests
that shared transcriptomic effects may emerge from common
chromatin pathology. Future studies may identify additional
gene disruptions in which alterations in mCA and enhancer dys-
regulation contribute to molecular pathology, expanding the role
of ‘‘methylopathies’’ in NDD.
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The accession number for the raw and aggregate data for bisulfite-seq, raw and gene-count data for RNA-seq, and raw and peak
call data for ChIP-seq reported in this paper is GEO: GSE147899.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animal husbandry
All animal protocols were approved by the Institutional Animal Care and Use Committee and the Animal Studies Committee of Wash-
ington University in St. Louis, and in accordance with guidelines from the National Institutes of Health (NIH). Mice were housed in a
room on a 12:12 hour light/dark cycle, with controlled room temperature (20-22C) and relative humidity (50%). Home cages
measured 28.5 cm x 17.5 cm x 12 cm and were supplied with corncob bedding and standard laboratory chow and water. All
mice were group-housed and adequate measures were taken to minimize animal pain or discomfort.
Transgenic animals
Male and female homozygous Dnmt3aflx/flx mice (Kaneda et al., 2004) were bred together for viral-mediated DNMT3A replacement
assay culture experiments. To generate the DNMT3A heterozygous mouse model, Dnmt3aflx/flx mice were crossed to CMV:Cre
(B6.C-Tg(CMV-cre)1Cgn/J) to generate Dnmt3aKO/+Cre:CMV+/ offspring. Dnmt3aKO/+Cre:CMV+/ progeny were bred to C57BL/
6J to outcross the cre recombinase and generate experimental genotype (DNMT3AKO/+). Mice were genotyped with ear-DNA by
PCR forDnmt3a andCre, and recombination was tested. Subsequent experimental animals were generated from Dnmt3aKO/+ males
mated to C57BL/6J females to generate Dnmt3aKO/+ and Dnmt3a+/+ experimental and control animals for experiments. Dnmt3aKO/+
females were not used for breeding to avoid social differences inmothering frommutant dams.Micewereweighed at a variety of time
points to assess growth.
Continued
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Neuro-2a cells (ATCC, CCL-131) were grown on coverslips and transfected with FLAG-tagged WT or mutant mouse DNMT3A plas-
mids and GFP plasmid. This FLAG-tag allows for quantification of transfected DNMT3A protein only instead of endogenous
DNMT3A. Coverslips were fixed with 4% paraformaldehyde in PBS for 20 minutes, permeabilized with 0.1% Triton X-100 in PBS
for 10 minutes, and blocked with 1% BSA in PBS for 1 hour all at room temperature. Coverslips were incubated overnight at 4C
in anti-DDDDK tag (FLAG-tag) primary antibody (Abcam, 1:5000, ab1162). Coverslips were then washed in PBS and incubated
for 1 hour at room temperature with fluorescent secondary antibody (ThermoFisher, 1:500, A-11011) and counterstained with DAPI.
Imaging
Images were captured using a Nikon A1Rsi confocal microscope with a 20x air objective. Laser settings were kept constant for each
image.
Analysis/Quantification
Cells were counted using an automatic threshold in FIJI and manually classified as displaying nuclear or non-nuclear signal by a
blinded observer. This was determined by evaluating the overlap of FLAG signal (DNMT3A) with DAPI signal (nucleus). For mutants
that did not reach expression levels comparable to the WT or for images that had too few positive cells, cell number was counted
manually. 8 separate transfections were run, with eachmutant being counted over 3 ormore independent experiments. Sample sizes
are as follows: WT, 15 images, 880 cells; W297del, 8 images, 435 cells; I310N, 8 images, 492 cells; S312fs11x, 12 images, 321 cells;
G532S, 9 images, 695 cells; M548K, 7 images, 333 cells; V665L, 6 images, 635 cells; Y735C, 16 images, 613 cells; R749C, 8 images,
667 cells; P904L, 7 images, 692 cells. While somemutants showed reduced protein expression, all proteins tested showed adequate
signal assessed as nuclear or non-nuclear. Percent nuclear was assessed per image and a generalized linear model was run
comparing each mutant to WT. P values for each mutant were then Bonferroni corrected. Localization to the nuclear periphery
was evident for the WT FLAG-tagged protein and all nuclear-localized mutants, but no consistent differences in this localization
was observed between WT and any mutants. We chose to use a generalized linear model with Bonferroni correction to allow for
us to compare ratios of percent nuclear signal while accounting for experimental and bioreplicates.
Modeling of DNMT3A disease mutations
HEK293T (ATCC, ACS-4500) or Neuro-2a cells (ATCC, CCL-131) were transfected with GFP and FLAG-taggedWT or mutant mouse
DNMT3A plasmids. Collected cell lysates were ruptured by 3 freeze/thaw cycles using liquid nitrogen, or sonication 42 hours after
transfection. Samples were then either used for western blotting (Neuro-2a cells), the in vitro radioactive methyltransferase assay
(HEK293T cells).
qRT-PCR
RNA isolated from neuronal cortical culture or mouse brain tissue was reverse transcribed using the High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems). Dnmt3a and Actb were measured by qPCR using the Power SYBR Green PCR Master Mix
and primers Actb (F:AAGGCCAACCGTGAAAAGAT, R:GTGGTACGACCAGAGGCATAC) and Dnmt3a (F:GGCCTTCTCGACTCCA-
GATG, R:TTCCTCTTCTCAGCTGGCAC). Relative quantity of Actb and Dnmt3a cDNA was determined by comparing the Ct of
each primer set in each sample to a standard curve and then normalizing the DNMT3A signal by the ACTB signal. We chose to
compare experimental conditions to WT samples using Student’s T-Tests with Bonferroni correction, as these are two normally
distributed groups (visually checked) with similar variability.
In vitro radioactive methyltransferase assay
30 ml of cell lysate from HEK293T cells was used in the methyltransferase reaction previously described (Russler-Germain et al., 2014).
Lysates were incubated at 37C for 20 hours in 5 ml reaction buffer of 20mMHEPES, 30mMNaCl, 0.5mMDTT, 1mMEDTA, 0.2mg/ml
BSA, 5 mM3 H-labeled SAM (PerkinElmer, NET155050UC) and 500 ng/ml Poly(dI-dC) substrate (Sigma P4929). Substrate was purified
(Macherey-Nagel NucleoSpin Gel and PCR Clean-up) and radioactivity measured using a scintillation counter. In instances where
DNMT3Amutant showed altered protein expression, cell lysate was re-balanced to match protein expression of WT DNMT3A. The ac-
tivity of endogenous DNMT3A present in the cells was accounted for by normalizing values to GFP alone. Only experimental replicates
whereWTDNMT3Ashoweda 1.5-fold increase compared toGFP alonewere used for subsequent analysis. Outliers beyond 2 standard
deviations above or below the mean were removed. Number of independent replicates are as follows: W297del, 18; I310N, 19;
S312fs11x, 4; G532S, 10; M548K, 15; V665L, 11; Y375C, 13; R749C, 7; P904L, 14. Significancewas assessed using a one-sample Stu-
dent’s t test, as we are comparing groups normalized to WT and GFP back to the normalized value of 1.
Viral-mediated DNMT3A replacement assay
Functional activity of DNMT3Amutants in cortical neurons was determined bymeasuring methylation build-up in vitro. Timedmating
of DNMT3Aflx/flx females and DNMT3Aflx/flx males was performed to collect embryonic cortical DNMT3Aflx/flx neurons at embryonic
day 14.5. At E14.5, DNMT3Aflx/flx cortical neurons from both male and female embryos were rapidly isolated and plated (DIV 0). On




DIV 3, neurons were either not perturbed or virally transduced with one of three conditions: 1) Cre only, 2) Cre andWT DNMT3A, or 3)
Cre and mutant DNMT3A. DNA and RNA were isolated on DIV 12.5 using the AllPrep DNA/RNA Kit (QIAGEN, 80204). DNA was used
for whole genome bisulfite sequencing, and RNA was used for qRT-PCR for DNMT3A. Results of pilot experiments (not shown) indi-
cate that at this time point mCA is not saturated and sensitive to total levels of DNMT3A activity. Number of independent replicates
are as follows: W297del, 5; S312fs11x, 4; G532S, 7; M548K, 6; V665L, 10; Y375C, 11; R749C, 6; P904L, 8. Buildup of methylation
over development was carried out without performing any viral transduction. Significance was assessed using a one-sample Stu-
dent’s t test or 1-way ANOVA.
Ultrasonic vocalization and analysis
A total of 76 DNMT3AKO/+ (n = 30, 16 male and 14 female) and litter-matched WT (n = 46, 25 male and 21 female) mice were used for
ultrasonic pup vocalization (USV) recording and analyzed as previously described (Barnes et al., 2017; Dougherty et al., 2013; Holy
and Guo, 2005). Dams were removed from the nest for a 10-minute acclimation, and individual pups had their body temperature
measured using an infrared laser thermometer. Pups were then removed from their nest and placed in a dark, enclosed chamber.
Ultrasonic vocalizations were recorded for 3 minutes with an Avisoft UltraSoundGate CM16 microphone and 416H amplifier using
Avisoft Recorder software (gain = 6 dB, 16 bits, sampling rate = 250 kHz). Pups were then weighed and returned to their nest and
littermates. All mice were recorded at postnatal days 5, 7, and 9, and on either day 11 or 15. Frequency sonograms were prepared
and analyzed inMATLAB (frequency range = 40 kHz to 120 kHz, FFT size = 256, overlap = 50%)with individual syllables identified and
counted according to previously publishedmethods (Dougherty et al., 2013; Holy andGuo, 2005). Significance was assessed using a
within-subjects repeated-measures ANOVA over time points 5-9, as these were when there was data from all experimental subjects,
and these are optimal testing times where number of calls was highest.
Marble burying
A total of 27 DNMT3AKO/+ (n = 13, 8male and 5 female) and litter-matchedWT (n = 14, 7male and 7 female) micewere used formarble
burying. Marble burying is a natural murine behavior and has been used to indicate repetitive digging as well as anxiety-related be-
haviors. Protocol was adapted frompreviously publishedmethods (Lazic, 2015;Maloney et al., 2019a). In brief, 8-week oldmicewere
placed in a transparent enclosure (28.5 cm x 17.5 cm x 12 cm) with clean aspen bedding and 20 dark bluemarbles evenly spaced in a
43 5 grid on top of the bedding. Animals explored freely for 30minutes. The number of buriedmarbles were counted every 5minutes
by two independent blinded observers.Marbles were considered ‘‘buried’’ if theywere at least two-thirds covered by bedding. Enclo-
sure andmarbles were cleaned thoroughly between animals. Significance was assessed using a within-subjects repeated-measures
ANOVA to determine if rate of buryingmarbles is different between genotypes. These statistical methods aremore appropriate than a
simple t test at 30 minutes, as mice may have buried all marbles before this time point, and significant changes in marble burying
behavior may have occurred at earlier time points in the assay.
Adult behavioral battery
A total of 72 DNMT3AKO/+ (n = 39, 18 male and 21 female) and litter-matched WT (n = 33, 15 male and 18 female) mice were used for
adult behavioral testing. Mice were housed in mixed genotype home cages with 2-5 animals per cage, and all tests were performed
during the light cycle. All experimenters were blinded to genotype during testing. For increased experimental rigor and reproduc-
ibility, we used three separate cohorts of mice to ensure quality and consistency in any observed phenotypes.
Testing started when mice were 3-4 months of age. The sequence of behavioral testing was designed to minimize carry-over ef-
fects across behavioral tests. Cohorts, ages, and testing order are in Table S5. Most assays were performed on cohorts 1 and 2 with
cohort 3 being performed to test for reproducibility in some assays. Because of differences in testing sequences and exposure of
mice to prior tests between cohorts, we examined separate cohorts individually and looked at combined cohorts (Table S5). Testing
was performed by the Washington University in St. Louis Animal Behavior Core.
One-hour locomotor activity
Locomotor activity was evaluated by computerized photobeam instrumentation in transparent polystyrene enclosures (47.6 cm x
25.4 cm x 20.6 cm) as previously described (Wozniak et al., 2004). Activity variables such as ambulations and vertical rearings
were measured in addition to time spent in a 33 cm x 11 cm central zone.
Sensorimotor battery
Mice were assayed in walking initiation, balance (ledge and platform tests), volitional movement (pole and inclined screens), and
strength (inverted screen) as previously described (Grady et al., 2006; Wozniak et al., 2004). For the walking initiation test, mice
were placed on the surface in the center of a 21 cm x 21 cm square marked with tape and the time for the mouse to leave the square
was recorded. During the balance tests, the time themouse remained on an elevated plexiglass ledge (0.75 cmwide) or small circular
wooden platform (3.0 cm in diameter) was recorded. During the Pole test, mice were placed at the top of a vertical pole with nose
pointing upward. The time for the mouse to turn and climb down the pole was recorded. For the inclined screen tests, a mouse
was placed (oriented head-down) in the middle of an elevated mesh grid measuring 16 squares per 10 cm angled at 60 or 90.
Time for the mouse to turn 180 and climb to the top was recorded. For the inverted screen test, a mouse was placed on a similar




screen and when the mouse appeared to have a secure grasp of the screen, the screen was inverted 180 and the latency for the
mouse to fall was recorded. All tests had a duration of 60 s, except for the pole test which was 120 s. Two separate trials were
done on subsequent days and averaged time of both trials was used for analysis. Data from the walking initiation, ledge, and platform
tests were not normally distributed and therefore analyzed using Mann-Whitney U tests.
Continuous and accelerating rotarod
Motor coordination and balancewere assessed using the rotarod test (Rotamex-5, Columbus Instruments, Columbus, OH) with three
conditions: a stationary rod (60 s maximum), a rotating rod at constant 5 rpm (60 s maximum), and a rod with accelerating rotational
speed (5 – 20 rpm, 180 s maximum) as previously described (Grady et al., 2006). This protocol is designed to minimize learning and
instead measure motor coordination, so testing sessions were separated by 4 days to allow for extinction. Testing included one trial
on stationary rod, and two trials on both the constant-speed rotarod and accelerating rotarod. Later time points in the constant speed
rotarod test failed tests of normality, as the majority of mice stayed on the rotating rod for all 60 s. However, data were analyzed with
two-way repeated-measures ANOVA.
Morris water maze
Spatial learning was assessed as previously described (Wozniak et al., 2004). Cued trials (visible platform, variable location) and
place trials (submerged, hidden platform, consistent location) were conducted in which escape path latency, length, and swimming
speeds were recorded. Animal tracking was done using a computerized system (ANY-maze, Stoelting). During cued trials, animals
underwent 4 trials per day over 2 consecutive days with the platform being moved to a different location for each trial with few distal
spatial cues available. Each trial lasted no longer than 60 s, with a 30-minute interval between each trial. Performance was analyzed
across four blocks of trials (2 trials/block). After a three-day rest period, animals were tested on place trials, in which mice were
required to learn the single location of a submerged platform with several salient distal spatial cues. Place trials occurred over 5
consecutive days of training, with 2 blocks of 2 consecutive trials (60 s trial maximum, 30 s inter-trial-interval after the mouse has
reached the platform) with each block separated by 2 hours. Mice were released into different quadrants over different trials. Place
trials were averaged over each of the five consecutive days (4 trials/block). One hour after the final block, a probe trial occurred (60 s
trial maximum) in which the platform is removed, and the mouse is released from the quadrant opposite where the platform had been
located. The time spent in pool quadrants, and the number of crossings over the exact platform location were recorded. DNMT3AKO/+
mice showed a small, but significant reduction in target zone time in cohort 2, though there was no difference in cohort 1. Additionally,
female mice had significantly faster swimming speeds than male mice across both genotypes (Table S5).
Elevated plus maze
Anxiety-like behaviors were examined using the elevated plus maze as previously described (Boyle et al., 2006). The apparatus con-
tains a central platform (5.5 cm x 5.5 cm) with two opposing open arms and two opposing closed arms (each 36 cm x 6.1 cm x 15 cm)
constructed of black Plexiglas. Mouse position is measured using beam-breaks from pairs of photocells configured in a 163 16 ma-
trix and outputs are recorded using an interface assembly (Kinder Scientific) and analyzed using software (MotoMonitor, Kinder Sci-
entific) to determine time spent, distance traveled, and entries made into open arms, closed arms, and the center area. Test sessions
were conducted in a dimly lit roomwith each session lasting 5 minutes and each mouse tested over 3 consecutive days. Data shown
are from day 1. All mice showed a decrease in time, distance, and entries into open arms on days 2 and 3. There was no significant
difference between genotypes in percent entries into open arms (Figure S4K; p = 0.137; unpaired Student’s T-Test) or total entries
into arms (data not shown), indicating that both genotypes explored themaze. Percent distance traveled in open arms showed similar
effects to percent time in open arms (Percent distance traveled: p = 0.027; unpaired Student’s T-Test). Analysis of these data in in-
dividual cohorts detected DNMT3AKO/+ significant effects for the percent of open arm time on the first day in cohorts 1 and 3, with no
evidence of an effect in cohort 2. Individual cohorts also showed no significant difference between genotypes in percent open arm
entries (Table S5) suggesting that mice explored the elevated plus maze sufficiently to detect anxiety-like behaviors.
Acoustic startle/prepulse inhibition
Sensorimotor gating was evaluated as previously described (Dougherty et al., 2013; Gallitano-Mendel et al., 2008; Hartman et al.,
2001). In short, mice were presented with an acoustic startle response (120 dB auditory stimulus pulse, 40 ms broadband burst)
and a pre-pulse (response to pre-pulse plus startle pulse). Stimulus onset began at 65 s, and 1ms force readings were obtained
and averaged to produce an animal’s startle amplitude. 20 startle trials were presented in 20 minutes. The first 5 minutes were an
acclimation period where no stimuli above the 65 dB background were presented. The session started and finished with 5 consec-
utive startle (120 dB pulse) trials. The middle 10 trials were interspersed with pre-pulse trials, consisting of an additional 30 presen-
tations of 120 dB startle stimuli preceded by pre-pulse stimuli of 4, 12, or 20 dB above background (10 trials for each PPI trial type). To
calculate percent pre-pulse inhibition, we used %PPI = 100 3 (ASRstartle pulse alone  ASRprepulse + startle pulse)/ASRstartle pulse alone.
Conditioned fear
Fear conditioning was done as previously described (Maloney et al., 2019a, 2019b). Mice were habituated to an acrylic chamber
(26 cm x 18 cm x 18 cm) containing a metal grid floor and an odorant and was illuminated by LED light which remained on for the




duration of the trial. Day 1 testing lasted 5 minutes in which, after a brief baseline period with no tone, an 80 dB tone sounded for 20 s
at trial time points 100, 160, and 220 s. A 1.0 mA shock (unconditioned stimulus) occurred within the last 2 s of the tone (conditioned
stimulus). Baseline freezing behavior during the first 2 minutes and the freezing behavior during the last 3 minutes was quantified us-
ing image analysis (Actimetrics, Evanston, Illinois). On Day 2, testing lasted for 8 minutes in which the light was illuminated but no
tones or shocks were presented. On Day 3, testing lasted for 10 minutes in which the mouse was placed in an opaque chamber
with a different odorant than the original test chamber. After a brief baseline period with no tone, the 80 dB tone began at 120 s
and lasted for the remainder of the trial and freezing behavior to the conditioned auditory stimulus was quantified for the remaining
8 minutes. DNMT3AKO/+ mice show elevated freezing levels during training and testing, which may reflect a baseline propensity to
freeze, stronger fear conditioning, or an emotional hypersensitivity to the foot-shock. Additionally, our data suggest that the
increased freezing in the DNMT3AKO/+mice does not appear to be due to an increased pain response, asmutantmice showed similar
levels of shock sensitivity. Evaluation of baseline freezing levels in individual cohorts only showed significance in one of the two co-
horts tested.
3-Chamber social approach
Sociability was assayed as previously described (Moy et al., 2004; Silverman et al., 2011). Mice were tested in a rectangular all-Plex-
iglas apparatus (each chamber measuring 19.5 cm x 39 cm x 22cm) divided into three chambers with walls containing rectangular
openings (5 cm x 8 cm) and sliding doors. The apparatus was in a room with indirect light and was cleaned between tests with Nol-
vasan solution. Stimulus mice were contained within a small stainless-steel withholding cage (10 cm height x 10 cm diameter; Galaxy
Pencil/Utility Cup, Spectrum Diversified Designs), allowing minimal contact between mice without allowing fighting. Between tests,
withholding cageswere cleanedwith 75%ethanol solution. A digital video camera recordedmovement of themousewithin the appa-
ratus and allowed for tracking with ANY-maze (Stoelting). Distance and time spent in each chamber and investigation zones sur-
rounding the withholding cages were recorded. Zones were defined as 12 cm in diameter from the center of withholding cages.
The test sequence consisted of 4 consecutive 10-minute trials in which the testmouse is placed in themiddle chamber and allowed
to freely explore the environment. In the first trial, themouse is placed in themiddle chamber with the doors to other chambers shut. In
the second trial, the mouse is placed in the middle chamber and can explore all three chambers of the task, allowing it to acclimate to
the environment. Neither genotype tested showed a preference toward a side of the chamber during this habituation. For the third
trial, a sex-matched novel conspecific was placed within a withholding cage with the other cage remaining empty. For the fourth trial,
the same sex-matched conspecific was in one withholding cage, while a new unfamiliar sex-matched stimulus mouse was placed in
the other withholding cage. The locations of stimuli micewere counterbalanced across groups for the third trial and randomized novel
or familiar for the fourth trial.
Reduced anxiety 3-chamber social approach
An add-on cohort was used to investigate sociability in a low-light environment with minimal distractions and stressors. A total of 37
DNMT3AKO/+ (n = 18, 9 male and 9 female) and litter-matchedWT (n = 19, 9 male and 10 female) mice 10-12 weeks of age were used.
These mice had not been used for previous behavioral analysis. Two additional DNMT3Amice were removed from the cohort prior to
analysis, as they appeared sickly and showed reduced movement. Social approach was carried out as described previously (Manno
et al., 2020). In brief, mice were tested in a rectangular clear acrylic apparatus (60 cm x 40.5 cm) separated into three equally sized
chambers divided by walls with sliding doors (6 cm x 6 cm), and with one cup placed in each of the edge chambers. The apparatus
was in an isolated, quiet roomwith minimal sound and low-light (270 lux). Three 10-minute phases were carried out. In the first phase,
the test mouse freely explored all chambers of the apparatus. In the second phase, a sex-matched conspecific mouse was added to
the one of the cups in the side chambers, and the test mouse was allowed to freely explore. In the third phase, a sex-matched novel
conspecific was added to the remaining empty cup and the test mouse was allowed to explore. Between experimental mice, the
apparatus was cleanedwith 70%ethanol. A digital video camera recorded the sessions andmouse location wasmeasured. For anal-
ysis, only the first 5 minutes of each phase was used, as mice rapidly habituate to this task (Manno et al., 2020).
Tissue collection
Brain tissue was dissected from DNMT3AKO/+ and WT littermate mice in ice-cold PBS, flash-frozen in liquid nitrogen, and stored at
80C.
Western blotting
Western blotting from cell culture
Neuro-2a cells were collected and combined with 2x laemmli buffer with 5% b-mercaptoethanol. Samples were passed through a
Wizard Column (Fisher, Wizard Minipreps Mini Columns, PRA7211), boiled for 5 minutes, and run on a BioRad 4%–12% acrylamide
gel at 125 V for 60 minutes. Samples were then transferred to a nitrocellulose membrane, which was bisected between 37kDa and
50kDa bands. Membranes were blocked with 3% bovine serum albumin in TBS-T for 1 hour at room temperature and then the lower
membrane was immunostained with anti-GFP (ThermoFisher, 1:2000, A-11122) while the upper membrane was immunostained with
anti-DDDDK (Abcam, 1:1000, ab1162) for 12-16 hours at 4C. All primary and secondary antibodies were diluted in 3%Bovine Serum
Albumin in TBS-T. Membranes were next washed with TBS-T, and then incubated for 1 hour at room temperature with IR-dye




secondary antibody (IRDye 800CW Donkey anti-Rabbit, LI-COR Biosciences, 1:15,000, product number: 926-32213). Blots were
then washed with PBS, imaged using the LiCOROdyssey XCL system, and quantified using Image Studio Lite software (LI-COR Bio-
sciences). FLAG (DDDDK) and GFP levels were normalized to a standard curve, and protein levels are expressed as normalized
DDDDK values divided by normalized GFP values to enable comparison of FLAG (DDDDK) levels between blots. Each blot included
a standard curve and WT samples. Outliers beyond 2 standard deviations above or below the mean were removed. Number of in-
dependent replicates are as follows: WT, 29; W297del, 7; I310N, 7; S312fs11x, 12; G532S, 7; M548K, 9; V665L, 7; Y375C, 8; R749C,
6; P904L, 7. Significance was assessed using a one sample Student’s T-Test, as protein expression levels were normalized to GFP
and WT, and mutant protein expression was compared to the normalized WT value of 1.
Western blotting from tissue
Brain tissue samples were homogenized with a dounce homogenizer in buffer with protease inhibitors (10mM HEPES pH 7.9, 10mM
KCl, 1.5mMMgCl2, 1mM DTT, 10mM EDTA). A portion of the lysate was removed and 1% SDS was added. Samples were boiled for
10 minutes, followed by a 10-minute spin at 15,000 g. Supernatant was collected and run through a Wizard Column (Fisher, Wizard
Minipreps Mini Columns, PRA7211), then diluted in LDS sample buffer with 5% b-mercaptoethanol. Samples were boiled for 5 mi-
nutes, run on an 8% acrylamide gel for 60 minutes at 125 V, and transferred to a nitrocellulose membrane. Membrane was bisected
between 75kDa and 100kDa. Membranes were blocked with 3%bovine serum albumin in TBS-T for 1 hour at room temperature, and
the upper membrane was immunostained with anti-DNMT3A (Abcam, 1:1000, ab13888) while the lower membrane was immuno-
stained with anti-a-Tubulin (Abcam, 1:1000, ab52866) for 12-16 hours at 4C. All primary and secondary antibodies were diluted
in 3% Bovine Serum Albumin in TBS-T. Membranes were next washed with TBS-T, and then incubated for 1 hour at room temper-
ature with IR-dye secondary antibody (IRDye 800CW Goat anti-Rabbit, or IRDye 800CW Goat anti-Mouse, LI-COR Biosciences,
1:15,000, product numbers: 926-32211 and 926-32210 respectively). Blots were then washed with PBS, imaged using the LiCOR
Odyssey XCL system, and quantified using Image Studio Lite software (LI-COR Biosciences). DNMT3A and a-Tubulin levels were
normalized to a standard curve, and protein levels are expressed as normalized DNMT3A values divided by normalized a-Tubulin
values to enable comparison of DNMT3A levels between blots. For brain region analysis, sample sizes of n = 4 per genotype (2
male and 2 female pairs) were used. For time course analysis, sample sizes of n = 2 per genotype (1 male and 1 female pairs)
were used for all time points except the 2-week time point in which n = 6 (3 male and 3 female pairs) was used. Significance was
assessed using a Student’s T-Test for brain regions, and a two-way ANOVA considering genotype and time to determine if there
was a detectable difference in protein expression over development.
Bisulfite sequencing
Whole genome bisulfite sequencing from cortical cultures
Samples were chosen for whole genome bisulfite sequencing if mutant andWT samples expressed equal amounts ofDnmt3amRNA
as measured by qRT-PCR (Figure S1F). DNA from cortical cultures was bisulfite converted and prepared for sequencing using the
Tecan Ovation Ultralow Methyl-Seq Kit (Tecan, 0335-32) and the Epitect Bisulfite Kit (QIAGEN, 59824) was used for bisulfite conver-
sion. We used alternate bisulfite conversion cycling conditions ([95C, 5 min; 60C, 20 min] x 4 cycles, 20C hold) to ensure lowest
possible bisulfite non-conversion rate. Libraries were PCR-amplified for 10-11 cycles. Libraries were then pooled and sequenced at a
depth of 0.01-0.03x genomic coverage using an Illumina MiSeq 2x150 through the Spike-In Cooperative at Washington University in
St. Louis. Significance was assessed using a one-sample Student’s t test, as we are comparing groups normalized to WT and GFP
back to the normalized value of 1.
Whole genome bisulfite sequencing from tissue
DNA was isolated from tissue using the DNEasy Kit (QIAGEN). 300 ng of DNA was prepared for sequencing using the Ovation Ultra-
low Methyl-Seq Kit (Tecan, 0335-32) with and the Epitect Bisulfite Kit (QIAGEN, 59824) was used for bisulfite conversion. For these
samples, 300 ng of DNAwas fragmented for 45 swith the Covaris E220 sonicator (10%Duty Factory, 175 Peak Incidence Power, 200
cycles per burst, milliTUBE 200mL AFA Fiber). DNA was then purified using 0.7 volumes of Agencourt Beads to select for long DNA
inserts for sequencing. We used alternate bisulfite conversion cycling conditions ([95C, 5min; 60C, 20min] x 4 cycles, 20C hold) to
ensure lowest possible bisulfite non-conversion rate. Libraries were PCR-amplified for 12 cycles. Libraries were then pooled and
sequenced using an Illumina MiSeq 2x150 through the Spike-In Cooperative at Washington University in St. Louis. Samples for
shallow-depth sequencing (Figures 4A and 4B) were sequenced at 0.01-0.03x genomic coverage. For brain region and liver methyl-
ation, n = 2 per genotype per region (one male pair, one female pair). For developmental time course methylation, n = 3-4 per geno-
type per time point, with at least one male and one female pair. 8-week cortex samples for deep sequencing (Figures 5 and 6A–6D;
Figures S6D–S6H) were sequenced at 25-27x coverage per genotype using two male and two female WT-DNMT3AKO/+ pairs (n = 4
per genotype). Samples were sequenced either using the HiSeq 3000 or NextSeq 500 at 2x150 or 1x150, respectively. For shallow
sequencing experiments, significance was assessed using either a two-sample Student’s T-Test to compare global methylation
values of the cortex between two genotypes or using a two-way ANOVA to compare broad methylation changes across a variety
of brain regions or time points. Genomic element comparisons were done using two-sample Student’s T-Tests with Bonferroni
correction.
Oxidative bisulfite sequencing from tissue
DNAwas isolated from tissue using the DNEasy Kit (QIAGEN, 69504). 450 ng of DNA was prepared for sequencing using the Ovation
Ultralow Methyl-Seq Kit (Tecan, 0335-32) with TrueMethyl oxBS plugin (Tecan, 0414-32). For these samples, 450 ng of DNA was




fragmented for 45 s with the Covaris E220 sonicator (10% Duty Factory, 175 Peak Incidence Power, 200 cycles per burst, milliTUBE
200mL AFA Fiber). DNA was then purified using 0.7 volumes of Agencourt Beads to select for long DNA inserts for sequencing. 2/3 of
the sample (300 ng of DNA)was used for OxBS libraries, whereas the remaining 1/3 (150 ng of DNA) was used for bisulfite libraries.
We used alternate bisulfite conversion cycling conditions ([95C, 5 min; 60C, 20 min] x 2 cycles; 95C, 5 min; 60C, 40 min; 95C,
5 min; 60C, 45 min; 20C hold) to ensure lowest possible bisulfite non-conversion rate. Bisulfite and oxidative bisulfite libraries were
PCR-amplified for 11 and 13 cycles respectively. Libraries were then pooled and sequenced using an Illumina MiSeq 2x150 through
the Spike-In Cooperative atWashington University in St. Louis. Samples were sequenced at 0.8-2.2x genomic coverage per replicate
(two male replicates per genotype). Genomic element comparisons were done using two-sample Student’s T-Tests with Bonferroni
correction.
Chromatin immunoprecipitation protocol
Chromatin immunoprecipitation was performed as previously described (Clemens et al., 2019; Cohen et al., 2011). Cerebral cortex
was dissected on ice in PBS fromDNMT3AKO/+ andWT littermates at 8-weeks old (n = 5 pairs, 3male, 2 female). The tissuewas flash-
frozen in liquid nitrogen and stored at 80C. Chromatin was fragmented with the Covaris E220 sonicator (5% Duty Factory, 140
Peak Incidence Power, 200 cycles per burst, milliTUBE 1mL AFA Fiber). ChIP was performed with H3K27ac antibody (0.025-
0.1mg; Abcam, ab4729) and libraries were generated using Ovation Ultralow Library System V2 (Tecan, 0344NB-32). Libraries
were sequenced using Illumina HiSeq 3000 with the Genome Technology Access Center at Washington University in St. Louis, typi-
cally yielding 15-40 million single-end reads per sample.
RNA sequencing
Total RNA isolation was carried out as previously described (Clemens et al., 2019). In brief, cerebral cortex was dissected in ice-cold
PBS from DNMT3AKO/+ andWT littermates at 8 weeks of age (n = 7 pairs, 3 male, 4 female). Cortex was lysed in RLT buffer following
the RNeasy Mini Kit (QIAGEN, 74104). RNA libraries were generated from 250 ng of RNA with NEBNext Ultra Directional RNA Library
Prep Kit for Illumina (NEB) using a modified amplification protocol (37C, 15 minutes; 98C, 30 s; [98C, 10 s; 65C, 30 s; 72C, 30 s]
x13; 72C, 5 minutes; 4C hold). RNA libraries were sequenced using Illumina HiSeq3000 1x50bp with the Genome Technology Ac-
cess Center at Washington University in St. Louis, typically yielding 15-30 million single-end reads per sample.
Craniofacial morphological analyses
A total of 24 sex-matched littermate paired mice (DNMT3AKO/+ n = 12, 7 male, 5 female; WT n = 12, 7 male, 5 female) across 3 time-
points (8 weeks DNMT3AKO/+ n = 4, WT n = 4; 20 weeks DNMT3AKO/+ n = 4, WT n = 4; 25 weeks DNMT3AKO/+ n = 4, WT n = 4) were
fixed in 4% paraformaldehyde through intracardiac perfusion. Whole mouse heads were scanned at the Musculoskeletal Research
Center atWashington University in St. Louis using a Scanco mCT40machine. CT images had voxel dimensions of 0.018mmandwere
reconstructed on a 2048x2048 pixel grid. The CT images were converted to 8bit images using ImageJ (https://imagej.nih.gov/ij/) and
surface reconstructions were acquired in Avizo (https://www.thermofisher.com/fr/en/home/industrial/electron-microscopy/
electron-microscopy-instruments-workflow-solutions/3d-visualization-analysis-software.html). Thirty-five three-dimensional land-
marks were collected from surface reconstructions of the cranium and mandible using Stratovan Checkpoint (https://www.
stratovan.com/products/checkpoint).
Generalized Procrustes Analysis in MorphoJ software was used to explore the differences and similarities of shape between the
DNMT3AKO/+ mice and their WT littermates as previously described (Hill et al., 2013). To control for possible differences in size, the
landmark coordinate data were natural log-transformed and analyzed with a linear regression model. Additionally, to localize differ-
ences in form to specific linear distances, landmark data were analyzed using Euclidean Distance Matrix Analysis (EDMA).
Bone length measurements
Wechose to quantify long bones thatmay directly relate to the height phenotype seen in patients. A total of 24 sex-matched littermate
pairedmice (DNMT3AKO/+ n = 12, 7male, 5 female;WT n = 12, 7male, 5 female) across 3 time-points (8 weeksDNMT3AKO/+ n = 4,WT
n = 4; 20 weeks DNMT3AKO/+ n = 4, WT n = 4; 25 weeks DNMT3AKO/+ n = 4, WT n = 4) were fixed in 4% paraformaldehyde through
intracardiac perfusion. Decapitated mouse bodies were scanned at the Musculoskeletal Research Center at Washington University
in St. Louis using a FaxitronModel UltraFocus100 Dual X-Raymachine. Bone lengths weremeasured using ImageJ. Data were taken
over three age time-points: 8 weeks, 20 weeks, and 25 weeks of age for male and female mice. There was no significant difference in
bone lengths based upon sex, but there was a difference based by age. To normalize for this age effect, data were expressed as
DNMT3AKO/+ bone lengths normalized to the WT lengths within groups. This also mirrors how human data are presented. Left
and right bones were measured and the larger was used for analysis.
QUANTIFICATION AND STATISTICAL ANALYSIS
Specific bioreplicate sample numbers (n), statistical tests used, boxplot and barplot summary statistics, and p value thresholds are
listed for each analysis in the corresponding figure legends. Violin plots were generated in R3.5.1 with ggplot2 using default density
functions. Additional information, including software used, is included below.




Statistical analysis for behavioral tests
Behavioral data were analyzed with R v3.3.2 (including the ANOVA function from the Car package in R (Fox andWeisberg, 2011)) and
plots were made using GraphPad Prism 7.03a. Normality was assessed using the Shapiro-Wilkes test and visually confirmed. Data
not normally distributed were analyzed using non-parametric tests, with the exception of continuous rotarod data. No consistent ge-
notype by sex interaction effects were observed for any tests. As expected, body weights were significantly different between males
and females and we therefore presented this data separated by sex. Data were collapsed across sex for presentation across all other
tests. Statistical testing was performed using planned assay-specific methods, such as using Student’s T-Tests for single parameter
comparisons between genotypes, and within-subjects two-way repeated-measures ANOVA for comparisons across time points. In-
dividual time points within repeated-measures tests were evaluated using Sidak’s multiple comparisons test. Individual cohorts were
analyzed separately and in aggregate with similar trends seen across cohorts (Table S5), therefore data from all cohorts were
included together.
Whole-genome bisulfite analysis
Bisulfite sequencing analysis was performed as previously described (Clemens et al., 2019). Briefly, data were adaptor-trimmed,
mapped to mm9, then deduplicated and called for methylation using BS-seeker2. Methylation levels across regions were assessed
using bedtools map -o sum, summing the number of readsmapping to Cs (supporting mC) and the amount of coverage in the region,
then dividing those two numbers (Quinlan and Hall, 2010). Hydroxymethylation was calculated as the percent methylation found in
the BS-seqminus the percentmethylation found in thematching oxBS-seq. Due to count noise, this occasionally resulted in apparent
negative hydroxymethylation. During bisulfite sequencing not all DNA can be efficiently bisulfite converted. Though our methods
should maximize the amount of converted unmethylated C, there is still a small percentage of unmethylated cytosines that are called
as methylated due to non-conversion (0.2%–0.3%). Due to this non-conversion, very lowly methylated regions (e.g., mCA at CpG
islands) may not show the same percent reduction in mCA as highly methylated regions. Data were visualized using the UCSC
genome browser (http://genome.ucsc.edu) (Kent et al., 2002). CpG islands were obtained from the UCSC table browser (Haeussler
et al., 2019), and CpG Shores were defined as the 8kb surrounding them. Average methylation per-sample is normally distributed in
all regions examined, and variance between genotypes is similar, fitting the assumptions of a 2-sample t test. Methylation levels for
individual elements are not necessarily normally distributed, so non-parametric tests were used instead. This approach to mirrors
multiple other studies quantifying mCA levels across the genome (Lister et al., 2013; Luo et al., 2017) where de novo calling of base-
pair resolution mCA DMRs is avoided due to low statistical power because of low mCA/CA levels at any individual site, and instead
focuses on quantification of mCA/CA levels in populations of pre-defined regions of known functional importance.
Differentially methylated region detection
BSmooth (Hansen et al., 2012) was used to call differentially CpGmethylated regions between DNMT3AKO/+ andWTmice, using four
bioreplicates. CG sites were filtered for requiring at least 2x coverage in all replicates and differentially methylated regions were called
with a statistical threshold of t-stat > 2.0. These regions were further filtered for a length > 100 bp and a requirement that the
smoothed per-rep methylation values were consistent. For hypomethylated regions all WT mCG/CG values needed to be greater
than any KOmCG/CG value, and for hypermethylated regions all KOmethylation values needed to be higher than all WTmethylation
values. Data fit the assumptions and requirements of BSmooth. Data were distributed evenly between chromosomes, and the over-
lap betweenDMRs and regions of interest fit a hypergeometric distribution, making a fisher’s exact test appropriate. In order to calcu-
late an expected overlap of DMRs and genomic regions, for each chromosome, an equal number of resampled DMRswere placed, at
random throughout the chromosome, as true DMRs, ensuring that the two do not overlap. From this, the overlap of genomic regions
with resampled DMRs was compared to the same overlap with true DMRs.
RNA sequencing analysis
RNA sequencing analysis was performed as previously described (Clemens et al., 2019). Briefly, raw FASTQ files were trimmed with
Trim Galore and rRNA sequences were filtered out with Bowtie. Remaining reads were aligned to mm9 using STAR (Dobin et al.,
2013) with the default parameters. Reads mapping to multiple regions in the genome were then filtered out, and uniquely mapping
readswere converted to BED files and separated into intronic and exonic reads. Finally, readswere assigned to genes using bedtools
coverage -counts (Quinlan and Hall, 2010).
For gene annotation we defined a ‘‘flattened’’ list of longest transcript forms for each gene, generated on Ensgene annotations and
obtained from the UCSC table browser. For each gene, Ensembl IDs were matched up to MGI gene names. Then, for each unique
MGI gene name, themost upstream Ensgene TSS and themost downstream TESwere taken as that gene’s start and stop. Based on
these Ensembl gene models, we defined TSS regions and gene bodies. Differentially expressed genes were identified using a Wald
test through DESeq2, running using default parameters on exonic reads from the DNMT3AKO/+ and WT.
To assess effects on other noncoding RNAs in the DNMT3AKO/+ strain, we realigned our RNA-seq data to all mouse noncoding
RNAs from RNAcentral (The RNAcentral Consortium, 2019), then ran DESeq2 on the counts from each noncoding transcript.





ChIP sequencing analysis was performed as previously described (Clemens et al., 2019). Briefly, reads were mapped to mm9 using
bowtie2 and reads were extended based on library sizes and deduplicated. Bedtools coverage –counts was used to quantify ChIP
signal at the transcriptional start site (TSS), gene body (GB), and transcriptional end site (TES) (Quinlan and Hall, 2010). edgeR was
then used to determine differential ChIP-signal across genotypes. Data were visualized using the UCSC genome browser (http://
genome.ucsc.edu) (Kent et al., 2002).
Controlled resampling
A similar resampling approach was used as previously described (Clemens et al., 2019). Briefly, for every entry in a sample set (e.g.,
DNMT3A-dysregulated genes), an entry in the control set (e.g., all other genes) with a similar desired characteristic (e.g., expression)
was selected, generating a control set of the same size and variable distribution as the sample set.
Identification of dysregulated enhancers
Enhancer regions from Clemens et al., 2019 were used, and enhancers dysregulated in the DNMT3AKO/+ were called using the same
method. Briefly, H3K27ac ChIP-seq reads were quantified in all acetyl peak regions, and edgeR was used to identify peaks with
significantly different amounts of H3K27ac signal. Peak regions were then divided into promoters, enhancers, and non-identified
peaks. Data fits the assumptions of BSmooth. Overlap between misregulated enhancers in different genotypes fit a hypergeometric
distribution.
GAGE
Gene set enrichment analysis for the gene sets described was performed using the Generally Applicable Gene-set Enrichment
(GAGE) program (Luo et al., 2009). The NDDmodels for comparison were chosen by searching for gene expression datasets meeting
the following criteria: 1) NDD/ASD models that have at least some similar features to DNMT3A disorders (e.g., ID, ASD) 2) generated
with the RNA-seq approach 3) analyzed brain tissue with enough similarity to our cortical analysis to justify a reasonable comparison.
Analysis was performed directionally on the shrunken, log-normalized exonic fold changes from DESeq2 analysis of DNMT3AKO/+
versus WT RNA-seq data. For each gene set, fold changes of genes in that set were compared to a background of all expressed
genes. Gene sets with an FDR q-value below 0.1 and an adjusted p value below 0.5 following expression matched resampling
repeated 1,000 times were considered statistically significant. Gene sets were selected for analysis from both human and mouse
studies of autism associated genes. SFARI genes (Abrahams et al., 2013) with scores of equal to or less than 3 were considered.
Date accessed: 6/20/2019.
GSEA
Gene Set Enrichment Analysis (GSEA) (Subramanian et al., 2005)(version 7.0, the Broad Institute of MIT and Harvard; https://www.
gsea-msigdb.org/gsea/downloads.jsp) was performed on shrunken, log-normalized exonic fold changes from DESeq2 between
DNMT3AKO+ and WT RNA-seq data. GSEA calculated a gene set Enrichment Score (ES) that analyzed genes were enriched in
the biological signal conduction on the MsigDB (Molecular Signatures Database; https://www.gsea-msigdb.org/gsea/msigdb).
Background was set to all expressed genes in this study and 1,000 permutations were set to generate a null distribution for enrich-
ment score in the hallmark gene sets and functional annotation gene sets. The gene sets database used for enrichment analysis were
‘c5.all.v7.0.symbols.gmt’, ‘c5.bp.v7.0.symbols.gmt’, ‘c5.cc.v7.0.symbols.gmt’and ‘c5.mf.v7.0.symbols.gmt’ and FDR < 0.1 was
defined as the cut-off criteria for significance.
Experimental design
Authenticated cell lines from ATCC (HEK293T, NEURO-2A) were used, and no mycoplasma contamination testing was needed.
Sample sizes were chosen based upon previously published studies using similar techniques. Statistical tests and exclusion criteria
(values beyond 2 standard deviations of the group mean) were similar to that of previously published studies and indicated in the
appropriate methods. For all animal experiments, experimenters were blinded to genotype during data collection. No treatment con-
ditions were used, so no samples or animals were allocated to experimental groups and no randomization was needed. Tests that
assume equal variance were only run if group variances were similar, otherwise alternative tests were used.
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Figure S1 
 
Figure S1. Localization, expression, and neuronal methylation are measured and disrupted in DNMT3A 
mutant cells, Related to Figures 1 and 2. 
(A) Example images of DNMT3A mutant protein immunocytochemistry in Neuro-2a cells. Scale bar = 20μm. (B) 
Full example immunoblot from Figure 1B with the truncated S312fs11x DNMT3A mutant protein indicated with an 
asterisk. (C) Quantification of immunoblot signal of DNMT3A (α-FLAG) from mutant proteins (n=6-30; unpaired T-
Test with Bonferroni correction). Though PWWP mutants show reduced protein expression, the remaining protein 
expression was adequate to assess cellular localization. (D) Genome wide mCA levels over time in WT neuronal 
cortical cultures, as measured by sparse WGBS (P=0.0035 effect by time, F(3,4)=29.45, n=2; one-way ANOVA). (E) 
Genome-wide mCA levels in DNMT3A mutant add-back cortical cultures at DIV 12.5 (n=7-11; unpaired T-Tests 
with Bonferroni correction). (F) qRT-PCR of Dnmt3a normalized to Actb for samples analyzed by WGBS. (n=4-11; 
one-sample T-Test with Bonferroni correction). (G) Genome wide mCG levels over time in neuronal cortical cultures, 
as measured by sparse WGBS (P>0.05 effect by time, F(3,4)=2.722, n=2; one-way ANOVA). (H) Genome-wide mCG 
levels in DNMT3A mutant add-back cortical cultures at DIV 12.5 (P>0.05; n=7-11; planned unpaired T-Tests with 
Bonferroni correction). ***, P<0.001; ****, P<0.0001. Bar graphs indicate mean and SEM. Box plots contain 10th-




Figure S2. Generation of DNMT3A haploinsufficiency model, Related to Figures 3,4,5,6 and 7. 
(A) Normalized Dnmt3a mRNA and protein expression from 2-week cortices of DNMT3AKO/+ and wild-type 
littermates (mRNA n=5, protein n=4, unpaired T-Test). (B) Protein expression of DNMT3A normalized to α-Tubulin 
measured by western blotting for cerebral cortex of DNMT3AKO/+ and wild-type littermates over developmental time 
(P=0.0157 effect by genotype, F(1,16)=7.303, n=2-5; two-way ANOVA). (C) Protein expression of DNMT3A 
normalized to α-Tubulin measured by western blotting for hippocampus, striatum, and cerebellum (P=0.0010 effect 
by genotype, F(1,18)=15.48, n=4; two-way ANOVA). *, P<0.05; ****, P<0.0001. Line plots indicate mean and SEM. 




Figure S3. Heterozygous disruption of DNMT3A leads to subtle skeletal differences, Related to Figure 3. 
(A,B) Measurements of (A) femur and (B) tibia by dual x-ray imaging in WT and DNMT3AKO/+ mice at 8, 20, and 25 
weeks of age. Lines indicate mean and SEM, with points indicating individual animals. (C) Standard deviations from 
WT mean for DNMT3AKO/+ sum of femur and tibia. (n=12; paired T-Test). Bar plot indicates mean and SEM. (D) 
Example dual x-ray image of mouse body with femur and tibia indicated. (E) Example of reconstructed skull from 
µCT imaging with landmarks used for craniofacial analysis shown. Red line indicates distances that are significantly 
larger in the WT compared to the DNMT3AKO/+, while blue line indicates distance that is significantly smaller in the 
WT compared to the DNMT3AKO/+ (P<0.05). (F,G) Principal component analysis of (F) cranial and (G) mandibular 




Figure S4. DNMT3AKO/+ mice show behavioral deficits with little change in movement ability, Related to Figure 
3. 
(A-J) Comparison of DNMT3AKO/+ and WT mice across a battery of sensorimotor assays. DNMT3AKO/+ mice show 
no significant difference in (A) walking initiation, or latency to fall off (B) ledge or (C) platform. (D-E) DNMT3AKO/+ 
mice show no difference compared to WT littermates in motor coordination as evidenced by time on a continuous (D) 
and accelerating (E) rotarod. (F) DNMT3AKO/+ mice show no difference in grip strength compared to WT littermates 
evidenced by no change in time on an inverted screen. (G) Mean % pre-pulse inhibition shows no significant difference 
between genotypes. DNMT3AKO/+ mice show a significant increase in time to (H) climb down a pole (P=0.016, 
n=21,27; unpaired T-Test), and to the top of a (I) 60° inclined screen (P=0.039, n=21,27; unpaired T-Test) and a (J) 
90° inclined screen (P=0.045, n=21,27; unpaired T-Test). (K) DNMT3AKO/+ mice show no deficit in elevated plus 
maze exploration as measured by percent entries into open arms. (L) Percent time spent freezing in contextual fear 
trials (P=0.0215 effect by genotype, F(1,50)=5.633, n=26; two-way repeated-measures ANOVA), and (M) cued fear 
trials (Baseline: P=0.0606 effect by genotype, F(1,50)=3.685; Cue: P<0.0001 effect by genotype, F(1,50)=17.03; n=26; 
two-way repeated-measures ANOVA with Sidak’s multiple comparisons test). (N) Shock sensitivity during 
conditioned fear test as indicated by the minimum shock needed to exhibit a behavioral response in mice shows no 
significant difference between genotypes. (O-R) Path distance to escape platform and swim speeds in the Morris water 
maze task. DNMT3AKO/+ mice show increased path distance to escape platform in both (O) cued trials (P=0.0012 
effect by genotype, F(1,46)=11.93; P=0.0433 interaction effect of genotype and trial block, F(3,138)=2.784; n=21,27; two-
way repeated-measures ANOVA) and (P) place trials (P=0.0408 interaction effect of genotype and trial block, 
F(4,184)=2.55 n=21,27; two-way repeated-measures ANOVA). No significant difference is seen in swimming speed 
during (Q) cued trials (P=0.0634 effect by genotype, F(1,46)=3.619 n=21,27; two-way repeated-measures ANOVA) 
and (R) place trials (P=0.098 effect by genotype, F(1,46)=2.845, n=21,27; two-way repeated-measures ANOVA). (S) 
DNMT3AKO/+ mice show no significant difference in time spent in the target quadrant of a Morris water maze 
compared to WT littermates. (T) DNMT3AKO/+ mice show a trend towards a reduction in platform crossings in the 
probe trial (P=0.0609; n=21,27; unpaired T-Test). (U) After 30 minutes, DNMT3AKO/+ mice have significantly fewer 
total marbles buried (P=0.0438; n=13,14; unpaired T-Test). *, P<0.05; **, P<0.01; ****, P<0.0001. Bar graphs and 






Figure S5. DNMT3AKO/+ mice do not show distance deficits in social approach task in low light environments, 
Related to Figure 3. 
(A-D) Social approach results from moderate-light apparatus show reduced activity in DNMT3AKO/+ mice. (A) 
Quantification of time spent in zones closest to each cup during phase with empty cup and novel conspecific (Empty, 
P=0.0026; Novel, P=0.0095; n=33,39; unpaired T-Test). (B) Time spent in zones closest to novel mouse and familiar 
mouse (Familiar, P=0.29; Novel, P=0.24; n=33,39; unpaired T-Test). (C) Preference Index for novel conspecific in 
the 3-chambered social approach task for WT and DNMT3AKO/+ mice using time spent in zones as calculated: 
Mouse/(Mouse+Object)x100 or Novel/(Novel+Familiar)x100 within each animal. (D) Total distance traveled during 
the 3-chambered social approach task for WT and DNMT3AKO/+ mice shows a broad reduction of distance traveled 
across all trials by DNMT3AKO/+ mice (P=0.018 effect by genotype, F(1,70)=5.862, n=33,39; two-way ANOVA). (E-
H) Social approach results from low-light apparatus with minimal experimenter presence show no differences between 
wild-type and DNMT3AKO/+ mice. (E) Quantification of time spent in zones closest to each cup during phase with 
empty cup and novel conspecific (Empty, P=0.85 Novel, P=0.49; n=19,18; unpaired T-Test). (F) Time spent in zones 
closest to novel mouse and familiar mouse (Familiar, P=0.75; Novel, P=0.86; n=19,18; unpaired T-Test). (G) 
Preference Index for novel conspecific in the 3-chambered social approach task shows no change for WT and 
DNMT3AKO/+ mice calculated using the same approach as C. (H) Total distance traveled during the 3-chambered 
social approach task for WT and DNMT3AKO/+ mice shows no reduction of distance traveled across trials by 
DNMT3AKO/+ mice (P=0.77 effect by genotype, F(1,105)=0.08, n=19,18; two-way ANOVA). **, P<0.01. Box plots 




Figure S6. Methylation and hydroxymethylation at developmental and gene regulatory sites, Related to Figures 
4,5, and 6. 
(A) Boxplots of CG methylation over postnatal development for regions called as having higher methylation in the 
frontal cortex of fetal versus adult tissue (Fetal-Specific DMR), or called as having higher methylation in the frontal 
cortex of the adult versus fetal tissue (Adult-specific DMR). DMRs from Lister et al. 2013, methylation data from 
Stroud et al. 2017. (Wilcoxon rank sum test with Bonferroni correction) (B) Boxplots of cortical methylation of WT 
and DNMT3A Nestin-cKO (Stroud et al. 2017) at 8 weeks postnatal within developmental DMRs shown in A 
(Wilcoxon rank sum test with Bonferroni correction). (C) mCG/CG (left) and hmCG/CG (right) from WT and 
DNMT3AKO/+ cortices in various genomic contexts as measured by oxidative bisulfite sequencing (paired T-Test with 
Bonferroni correction). (D) Boxplots of cortical methylation of WT and DNMT3AKO/+ at 8 weeks postnatally within 
DMRs defined in the DNMT3AKO/+ model. DMRs are called on this data set, so no additional statistics were run on 
genotype differences. (E) Heatmap of log2 odds-ratios of observed and background (derived from resampling, see 
methods) overlap between DNMT3AKO/+ cortex CG-DMRs and various genomic regions. Color indicates magnitude 
of enrichment (Observed/resampled), number indicates -log10 p-value for Fisher-exact tests between observed and 
resampled values. (F) Smooth scatter plots of WT and DNMT3AKO/+ mCA/CA for classes of genomic regions. (G) 
Boxplot of fold-changes in H3K27ac signal in the DNMT3AKO/+ and WT cortex for enhancers found within TADs 
with high (top 10%) and low (bottom 10%) average levels of mCA/CA. (H) Boxplot of fold-changes in H3K27ac 
signal in the DNMT3AKO/+ and WT cortices from enhancers containing hypo/hyper CG-DMRs, and from enhancers 




Figure S7. Functional networks of genes and enhancers disrupted in DNMT3AKO/+ cortices, Related to Figures 
6 and 7. 
(A) Volcano plot of DESeq log2 fold changes of the DNMT3AKO/+ versus WT. Genes reaching a significance of 
padj.<0.1 are colored in red (Supplementary Table 3). (B) Boxplot of DESeq log2 fold changes from noncoding RNAs 
from RNAcentral, organized by RNA type. (C) Top ten up- and down-regulated Gene Ontology terms from Broad 
GSEA Molecular Signatures Database version 7.0 (Subramanian et al., 2005). All terms are significant at an FDR<0.1. 
(D) Mean mCA sites/kb in WT and DNMT3AKO/+ cortex (top) and number of mCA sites/kb lost in the DNMT3AKO/+ 
cortex (bottom) for enhancers found within genes called as significantly dysregulated in the DNMT3AKO/+ (n=4; paired 
T-Test with Bonferroni correction). (E) Boxplot of fold-change in H3K27ac signal in enhancers found within genes 
called as significantly dysregulated in the DNMT3AKO/+ (n=5 biological replicates of DNMT3AKO/+ and WT; 
Wilcoxon test) (F) Boxplot of DESeq log2 fold changes of in gene expression in the DNMT3AKO/+ versus WT, for 
genes containing enhancers with hypo-CG-DMRs, genes containing enhancers with hyper-CG-DMRs, and all other 
genes containing enhancers. (G) GAGE analysis of developmental expression modules (Parikshak et al., 2013). 
Significant modules (q-value<0.1) are colored in red (left). Expression matched resampling of each gene set was 
performed 1,000 times and analyzed using GAGE for enrichment in DNMT3AKO/+ fold-change data (gray violin). 
This was compared with the true gene set p-value (red point) to test for significance (right). Only the direction of 
dysregulation in which the gene sets showed the highest significance (i.e. DNMT3AKO/+ greater or less) is shown. (H) 
Expression matched resampling of GAGE analysis for gene sets displayed in Figures 6 and 7. Only the direction of 
dysregulation in which the gene set showed significance (i.e. DNMT3AKO/+ greater or less) is shown. Note: legend is 
shared in D and E. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001. 
 
  
Table S1. Table of DNMT3A Mutations and Patient Phenotypes, Related to Figure 1, Figure 2, Figure S1 
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